Clinical trial NCT03399318
Conditions: Malaria Seizures Coma Parasitemia Hyperpyrexia Fever
Keywords: HRP2
Sponsor: University of Rochester
Start date: 2019-01-07; Completion date: 2022-12-02
Enrollment: 256 participants; Allocation: RANDOMIZED; Intervention model: PARALLEL

Brief summary:
The study will examine whether prophylactic and scheduled treatment with acetaminophen and ibuprofen can decrease the maximum temperature experienced during the acute illness in children with CNS malaria.

Detailed description:
Despite ongoing eradication efforts, malaria remains a major public health challenge in Africa where annually, \~250,000 children with malaria experience a neurologic injury with subsequent neurodisability. In other central nervous system (CNS) disorders, fever is a recognized cause of worsening secondary neurologic injury and ex-tensive efforts are made to avoid hyperthermia or induce hypothermia for neuroprotection. Evidence indicates that among children with CNS malaria a higher temperature during the acute illness is a risk factor for post-infectious neurologic sequelae. As such, aggressive antipyretic therapy may be warranted, at least among children with complicated malaria who are at substantial risk of brain injury. Previous clinical trials conducted primarily in children with uncomplicated malaria and using only a single antipyretic medication have shown limited benefits in terms of fever reduction; however, no studies to date have examined malaria fever management using dual therapies. Enthusiasm for aggressive fever reduction measures among clinicians caring for children with malaria has been curbed by in vitro findings that malaria parasite replication slows at higher temperatures and a single clinical trial in which peripheral parasite clearance was slower in children receiving treatment for fever. However, the relationship between temperature and malaria parasite behavior is complex. Additional in vitro data suggest that at febrile temperatures uninfected red blood cells (RBCs) are more likely to adhere to infected RBCs, worsening the process of sequestration, increasing the parasite burden obstructing microvascular cerebral blood flow, and perhaps contributing to ongoing immunopathogenesis in CNS malaria. In this exploratory clinical trial of aggressive antipyretic therapy, children hospitalized with CNS malaria will be randomized to usual care (acetaminophen every 6 hours for a temperature ≥ 38.5ºC) vs. prophylactic acetaminophen and ibuprofen every 6 hours for 72 hours. This proof-of-concept study will determine whether aggressive antipyretic therapy results in a lower mean maximum temperature relative to usual care. Serial quantitative levels of histidine rich protein 2 (HRP2), a P. falciparum-specific protein that facilitates estimates of whole body parasite burden and CNS parasite sequestration, will also be collected to clarify the relationship between antipyretic use and in vivo parasite behavior. Findings from this study will determine whether a Phase III clinical trial of aggressive antipyretics for neuroprotection in pediatric CNS malaria should be undertaken. This study will take place in Zambia and Malawi, where prior NIH-funded collaborations have assisted in developing the substantial infrastructure needed to undertake a clinical trial of this nature.

Arms: arm 1: regardless of temperature, children allocated to this arm will receive acetaminophen (30 milligrams (mg)/ kilogram (kg) load then 15mg/kg Q6 hours) and ibuprofen (10mg/kg Q 6 hours) for 72 hours. Pediatric syrup formulations of both agents will be administered orally or via nasogastric tube. For temperatures over 38.5 degrees Celsius, placebo will be added and if the fever persists, a cooling fan will be added. arm 2: will receive placebo for acetaminophen and placebo for ibuprofen. If they have a temperature over 38.5 degrees Celsius, they will receive acetaminophen (15mg/kg, Q6 hours), as needed. If the fever persists, a cooling fan will be added.
Interventions: intervention 1: Acetaminophen intervention 2: Ibuprofen intervention 3: placebo for acetaminophen intervention 4: placebo for ibuprofen
Intervention descriptions: intervention 1: 30 mg/kg load then 15mg/kg Q6 hours for the Aggressive Antipyretic Arm

Acetaminophen is also given to children in the placebo arm when they have a fever over 38.5 degrees Celsius during scheduled clinical assessments intervention 2: 10 mg/kg Q6 hours for the Aggressive Antipyretic Arm intervention 3: placebo for acetaminophen for children in the Usual Care arm

For children in the Aggressive Antipyretic Arm, when they have a temperature over 38.5 degrees Celsius they are treated with a placebo intervention 4: placebo for ibuprofen

Protocol documents:
ICF_005.pdf: 
English Consent Form: Randomized Trial of Aggressive Antipyretics for Malaria
Version 4.5
Page 1 of 5
11 Oct 2018
MALAWI site-specific
INTRODUCTION
Your child has malaria and needs admission to the hospital for care. We are seeking your permission 
for your child to participate in a clinical trial of antipyretics (Panadol and Brufen) for fever reduction. 
Panadol and Brufen are medications commonly used for treating fevers in children, but usually 
children with malaria only receive Panadol and they are only given a medication for fever reduction if 
their fever reaches 38.5ºC or higher. 
In previous research we found that children with higher fevers during their acute malarial illness had a 
greater risk of developing neurologic problems after they recovered from the infection and we know 
that in other conditions affecting the nervous system, therapies that prevent the patient from becoming 
febrile result in better neurologic outcomes. 
PURPOSE OF THE RESEARCH
This study is therefore designed to determine if there is a reduction in fevers in the children who 
receive aggressive antipyretic therapy vs. routine care.
PROCEDURES AND STUDY SCHEDULE
If you choose to take part in this study, we are going to randomly assign children to one of two 
groups, either the ‘usual care’ group, or the ‘aggressive antipyretic therapy’ group.  In the ‘usual care’ 
group, children will get treatment with Panadol if they get a temperature of 38.5ºC or higher, and will 
also get Brufen if the temperature remains high on Panadol alone. In the same ‘usual care’ group, 
children will receive inactive medication (placebo) initially and active medication only if their 
temperature goes above 38.5ºC.  In the ‘aggressive antipyretic therapy’ group, children will get 
Panadol and Brufen immediately and then every 6 hours for 72 hours even if they do not have a 
temperature above 38.5ºC. We do not know if giving Panadol and Brufen immediately and together 
will result in less fevers. In both groups children who have a fever will receive active medication to 
reduce that fever.  Some will receive the active medication before a fever reaches 38.5, if their 
temperature goes over 38.5 despite the active medication they will be given inactive medication 
(placebo) and a fan. We do not know if giving Panadol and Brufen immediately and together will 
result in less fevers. It is important to remember that all children who have a fever will receive 
treatment for their fever.
If you agree to allow your child to participate in this research study, your child will be assigned by 
chance (like flipping a coin) to receive aggressive antipyretics vs. ‘usual care’. Your child will have 
an equal chance of being in either of the two groups. Neither you nor your child’s doctor will know 
which group he or she is assigned to. 
The medications are both in liquid form which will be given by mouth every 6 hours for the next 3 
days. If your child is unable to swallow the medication, we will place a tube in your child’s nose 
going into the stomach and the medication will be delivered through that tube until your child wakes 
up. Once your child is awake and able to take the medication, we will remove this tube. 
All children in this study will have a small sticker placed in their armpit to measure their temperature 
for 3 days. All children in this study will have blood taken every 6 hours by finger pricks to check the 
parasite count, glucose and kidney function. The total volume of blood taken over the full course of 
the study will be less than 2 mls. If your child is confused or sleepy from the malaria and cannot be 
easily awakened, we will also place some metal discs on the head attached with glue to record your 
child’s brain activity. This is to measure continuous electroencephalogram (EEG) activity, or the 
electrical activity in the brain. The EEG will allow us to know if your child is having any seizures that 
we cannot see by just looking at the child. Seizures can happen in the brain and not be apparent by 
just looking. 
RSRB Approval Date: 12/8/2020
Expiration Date: 12/7/2021


English Consent Form: Randomized Trial of Aggressive Antipyretics for Malaria
Version 4.5
Page 2 of 5
11 Oct 2018
MALAWI site-specific
POTENTIAL RISKS
If your child is in this study and they are unable to swallow, then they will have a nasogastric 
tube (NGT) placed so that the study medications can be given to them. If your child is not in 
the study, no NGT will be placed today. This tube may cause nasal or throat irritation or 
bleeding. 
In some cases, the NGT might be misplaced. This is very rare since the members of staff who 
insert the tubes are well trained. In cases where this happens, it could result in the medication 
going into the child’s lungs and would require removal of the tube and further treatment, like 
suction. 
As part of the research, when your child is pricked for malaria parasite counts, we will take an 
extra small tube of blood (hold up capillary tube).This may cause minimal discomfort (pain).  
Malaria can cause problems with bleeding, poor liver function and poor kidney function. It is 
possible that the medications given in this clinical trial could worsen the problems caused by 
malaria. The Brufen could cause your child to have problems with bleeding. We will monitor 
for this closely and if we see any signs of problems with bleeding, we will stop the study 
medications. The Panadol and Brufen are generally safe medications but stomach irritation 
and stomach pain can result from taking these medications. These medications might also 
worsen problems the malaria causes to your child’s liver and kidneys. We will monitor for 
signs that the medications are causing problems and stop treatment if needed. If your child 
experiences any adverse effects from the drug, we will provide care and treatment plus any 
other assistance as may be deemed necessary.
The glue and metal discs for the EEG are not harmful although the glue has a strong smell and 
some people get mild skin irritation where the glue and electrodes are placed.  
POTENTIAL BENEFITS
The EEGs may alert us to seizures we cannot detect otherwise and will allow us to treat 
these seizures, which might otherwise go without treatment possibly resulting in brain 
injury. 
If your child is randomized to aggressive antipyretics, your child may be more 
comfortable during this admission since in addition to fever reduction, these 
medications also treat pain (e.g. the headache usually associated with malaria).
YOUR RIGHTS
Your child’s participation in this research study is entirely voluntary. 
If you do not wish for your child to participate in this clinical trial, your child will 
continue to be cared for here. No care will be withheld. Your child’s fevers will be 
treated with the ‘usual care’ detailed above. This will include treatment with Panadol, 
additional treatment with Brufen if Panadol does not lower the fever 
If you agree to your child’s participation now, but later decide you do not wish for your 
child to be part of our study, you may withdraw the child from participation at any 
time. 
RSRB Approval Date: 12/8/2020
Expiration Date: 12/7/2021


English Consent Form: Randomized Trial of Aggressive Antipyretics for Malaria
Version 4.5
Page 3 of 5
11 Oct 2018
MALAWI site-specific
On the side of investigators, there are no foreseen circumstances under which the 
principal investigator may terminate a subject’s participation in the study. While your 
child is participating in this study, we will provide you immediately with any new 
findings about this study or the antipyretic medications. 
PRIVACY AND CONFIDENTIALITY
Conversations you or your child may have with any of the medical personnel will 
remain confidential.
To limit the risk to your privacy, when we record data in the research file, a study ID 
and not your child’s name will be recorded
The information about your child from this study will be kept at Queen Elizabeth Central 
Hospital (QECH) or University Teaching Hospital (UTH) in locked study offices.
For all study purposes, your child will be assigned a study identifier and information 
sent outside the hospital will include this identifier, not your child’s name. 
The study records will be kept for a minimum of three years following the completion of 
the study.
People who have access to this information include:
o
Research staff who will be reviewing your child’s medical records and recording 
information important for the study in a research file. 
o
Independent Study Monitors
o
The Research Ethics Committees at this hospital and at the University of 
Rochester, the Malawi Pharmacy, Medicines & Poisons Board and the US 
National Institutes of Health.
By signing this consent form you are agreeing that these entities can have access to your 
child’s records
Your privacy will be protected to the maximum extent allowable by law.
COSTS AND COMPENSATION
There are no anticipated costs to be incurred by individual as a direct result from 
participating in this study.
If you agree for your child to be in this study, we will provide you and your child with 
transportation home or funds for transportation home.
CONTACT INFORMATION
A description of this clinical trial will be available on www.ClinicalTrials.gov, as required by U.S. 
law.  This website will not include information that can identify you.  At most, the website will 
include a summary of the results.  You can search this Web site at any time.
If you have any questions about your child’s participation as a subject in human research or need to 
contact someone about a research-related injury, you may contact the investigators in charge. Or, you 
may contact the Chair for the Research and Ethics Committee:
Dr. Gretchen Birbeck 0995-008069
Dr. Karl Seydel 0999-452989
Dr. Mac Mallewa 0995-835083
QECH, Blantyre Malaria Project
PO Box 30096
Blantyre #3
College of Medicine Research and Ethics 
Committee
Private Bag 360, Chichiri
Blantyre 3, Malawi
Tele 01874377
Fax 01874740
Email: comrec@medcol.mw
     
RSRB Approval Date: 12/8/2020
Expiration Date: 12/7/2021


English Consent Form: Randomized Trial of Aggressive Antipyretics for Malaria
Version 4.5
Page 4 of 5
11 Oct 2018
MALAWI site-specific
******************************************************************************
DOCUMENTATION OF INFORMED CONSENT
“I voluntarily agree for this child to participate in this study”
Name of the child _________________________________________________
Name of guardian_________________________________________________
Guardian’s relationship to child _______________________________________________
_______________________________________________ Date _____________ (dd/MMM/yyyy)
Parent/guardian signature or thumbprint
I affirm that I have witnessed the above explanation to the child’s guardian, and that the guardian 
has confirmed that s/he understands and has given consent to the child’s enrollment in this study.
Name of Witness_____________________________________________________
Signature of Witness_________________________________Date______________(dd/MMM/yyyy)
Name of Nurse/Doctor Obtaining Consent _____________________________________
Signature of Nurse/Doctor_______________________________ Date __________(dd/MMM/yyyy) 
STUDY ID Assigned: FCS______________
******************************************************************************
Please accept a copy of this form to keep.
RSRB Approval Date: 12/8/2020
Expiration Date: 12/7/2021


English Consent Form: Randomized Trial of Aggressive Antipyretics for Malaria
Version 4.5
Page 5 of 5
11 Oct 2018
MALAWI site-specific
RSRB Approval Date: 12/8/2020
Expiration Date: 12/7/2021

Prot_SAP_003.pdf: 
 
Aggressive Antipyretics for Fever 
 
 
Control in CNS Malaria 
 
 
Version 5.3 
21 Jan 2021 
Page 1 of 33 
 
AGGRESSIVE ANTIPYRETICS IN CNS MALARIA: A RANDOMIZED-CONTROLLED TRIAL  
ASSESSING ANTIPYRETIC EFFICACY AND PARASITE CLEARANCE 
 
 
Principal Investigator 
Gretchen L. Birbeck, MD MPH DTMH  
Professor, University of Rochester, Departments of Neurology and Public Health, Center for Health & 
Technology 
Research Director, Epilepsy Division 
265 Crittenden Blvd 
CU 420694 
Rochester, NY 14642-0694, USA 
US Office +1-5172734265 
US Cell +1-5175050283 
SkypeIN +1-5176390272  
In Malawi +265-995008069 
In Zambia +260-978086957 
Fax +1-5175075440 
Email Gretchen_Birbeck@URMC.Rochester.edu  
SkypeID:  muyucottage 
Contents 
ADMINISTRATIVE INFORMATION ...................................................................................... 3 
1. TITLE ................................................................................................................................ 3 
2. TRIAL REGISTRATION ........................................................................................................ 3 
3. PROTOCOL VERSION .......................................................................................................... 3 
 
4. FUNDING ........................................................................................................................... 3 
5. ROLES AND RESPONSIBILITIES ........................................................................................... 3 
5(a). Protocol contributors .................................................................................................. 3 
5(b)Trial sponsor ................................................................................................................. 5 
5(c) Role of study sponsor and funders ............................................................................... 5 
5(d) Composition of Advisory Committee, Local Study Monitor and Data Safety Monitoring Board
 
5 
6. BACKGROUND AND RATIONALE ........................................................................................ 9 
6(a) Description of research question ................................................................................. 9 
7. OBJECTIVES .................................................................................................................... 13 
7.1 Hypothesis ................................................................................................................... 13 
7.2  Primary objectives ...................................................................................................... 13 
7.3 Secondary objectives ................................................................................................... 13 
8. TRIAL DESIGN ................................................................................................................. 14 
METHODS: PARTICIPANTS, INTERVENTIONS, AND OUTCOMES ............................ 14 
9. STUDY SETTING .............................................................................................................. 14 
10. ELIGIBILITY CRITERIA ................................................................................................... 14 
10.1 Inclusion Criteria ...................................................................................................... 14 
10.2 Exclusion Criteria...................................................................................................... 14 
11. INTERVENTIONS ............................................................................................................ 15 
11(a) Interventions ............................................................................................................ 15 
11(b) Criteria for discontinuing or altering interventions ................................................ 15 
11(c) Strategies to improve adherence .............................................................................. 16 
11(d) Relevant concomitant care ....................................................................................... 16 
12. OUTCOMES ................................................................................................................... 16 
12.1 Primary outcome measures ....................................................................................... 16 


 
Aggressive Antipyretics for Fever 
 
 
Control in CNS Malaria 
 
 
Version 5.3 
21 Jan 2021 
Page 2 of 33 
12.2 Secondary outcome measures .................................................................................... 16 
12.3 Additional demographic and clinical data to be collected ........................................ 17 
13. PARTICIPANT TIMELINE ................................................................................................. 18 
14. SAMPLE SIZE ................................................................................................................. 19 
15. RECRUITMENT .............................................................................................................. 20 
15.1 Blantyre. .................................................................................................................... 20 
15.2 Lusaka. ....................................................................................................................... 20 
METHODS: ASSIGNMENT OF INTERVENTIONS ............................................................ 20 
16. ALLOCATION ................................................................................................................ 21 
16(a) Sequence generation. ............................................................................................... 21 
16(b) Allocation concealment mechanism. ........................................................................ 21 
17. BLINDING...................................................................................................................... 21 
METHODS: DATA COLLECTION, MANAGEMENT, AND ANALYSIS ......................... 21 
18. DATA COLLECTION METHODS ....................................................................................... 21 
18.1 Collection of data ...................................................................................................... 21 
18.2 Retention of subjects .................................................................................................. 22 
19. DATA MANAGEMENT .................................................................................................... 22 
20. STATISTICAL METHODS ................................................................................................. 23 
METHODS: MONITORING ..................................................................................................... 24 
21. DATA MONITORING ....................................................................................................... 24 
23. AUDITING ..................................................................................................................... 27 
ETHICS AND DISSEMINATION ............................................................................................ 27 
24. RESEARCH ETHICS APPROVAL ....................................................................................... 27 
25. PROTOCOL AMENDMENTS ............................................................................................. 28 
26. CONSENT ...................................................................................................................... 28 
27. CONFIDENTIALITY ........................................................................................................ 28 
28. DECLARATION OF INTERESTS ........................................................................................ 29 
29. ACCESS TO DATA .......................................................................................................... 29 
30. ANCILLARY AND POST-TRIAL CARE .............................................................................. 29 
31. DISSEMINATION POLICY ................................................................................................ 29 
32. INFORMED CONSENT MATERIAL (FINAL ENGLISH VERSION WILL BE TRANSLATED INTO THE 
APPROPRIATE LOCAL LANGUAGES) ..................................................................................... 29 
 
 
 
 


 
Aggressive Antipyretics for Fever 
 
 
Control in CNS Malaria 
 
 
Version 5.3 
21 Jan 2021 
Page 3 of 33 
Administrative Information 
1. Title 
 
Aggressive Antipyretics in CNS Malaria: A Randomized-Controlled Trial Assessing Antipyretic Efficacy 
and Parasite Clearance Effects 
 
2. Trial registration 
 
This trial is registered with ClinicalTrial.gov (NCT03399318) and with the Pan African Clinical Trials 
Registry (PACTR201804003255157). 
 
3. Protocol version  
 
Issue date: 21 Oct 2020 
Authors: KBS, GLB, MM 
Version #: 5.2 
 
Revision Chronology: GLB revision to version 3.0 30Sep2016 
4. Funding 
 
Funded by the US NIH NIHR01NS102176 
 
5. Roles and responsibilities 
 
5(a) Protocol contributors 
Gretchen L. Birbeck, MD MPH DTMH  
Principal Investigator 
Professor, University of Rochester, Departments of Neurology and Public Health, Center for Health & 
Technology 
Research Director, Epilepsy Division 
265 Crittenden Blvd 
CU 420694 
Rochester, NY 14642-0694, USA 
US Office +1-5172734265 
US Cell +1-5175050283 
SkypeIN +1-5176390272  
In Malawi +265-995008069 
In Zambia +260-978-086-957 
Fax +1-5175075440 
Email Gretchen_Birbeck@URMC.Rochester.edu  
SkypeID:  muyucottage 
 
Karl Seydel, MD PhD 
Co-Investigator and local PI in Malawi 
Dept. of Osteopathic Medical Specialties 
College of Osteopathic Medicine 
909 Fee Road, West Feel Hall, Room B305-B  
East Lansing MI  48824-1315, USA 
US Office +1-5173533211 
In Malawi +265-999452989 
Fax +1-5174321062 


 
Aggressive Antipyretics for Fever 
 
 
Control in CNS Malaria 
 
 
Version 5.3 
21 Jan 2021 
Page 4 of 33 
Email seydel@msu.edu  
 
Manoj Mathews, MBChB, MMED Pediatrics and Child Health 
Co-Investigator 
National Paediatric Coordinator – Ministry of Health 
Consultant Paediatrician – UTHs Children’s Hospital 
Honorary Lecturer UNZA SOM 
University Teaching Hospital 
Nationalist Ave 
RW-1X 
Lusaka, Zambia 
Cell +260-977625727 
Email m_s_mathew@yahoo.com  
 
Musaku Mwenechanya, MBChB, MMED Pediatrics and Child Health 
Co-Investigator 
Head, Clinical Care 
UTH Lusaka Children’s Hospital 
Nationalist Ave 
RW-1X 
Lusaka, Zambia 
Tele +260-966722966 
Email mmusaku@gmail.com  
 
Suzanna Mwanza, MBChB, MMED Pediatrics and Child Health 
Co-Investigator 
Consultant Paeditrician and Head of Department for Paediatrics & Child Health 
Chipata Central Hospital 
P.O. Box 510119 
Chipata, Zambia 
Cell +260-977674471 
Work +260-961517604 
Email mwanzasue@yahoo.co.uk  
 
Michael McDermott, PhD 
Co-Investigator 
Professor of Biostatistics and Computational Biology 
265 Crittenden Blvd, CU 420630 
Rochester, NY  14642-0630, USA 
Tele +1-5852756685 
Fax +1-5852731031 
Email MikeM@bst.rochester,edu  
 
Archana Patel, MD, MPH  
Co-Investigator  
Instructor in Neurology  
300 Longwood Ave 
Boston, MA 02115-5724, USA  
Cell (+1) 617-355-7970 
Work (+1) 617-730-4850 
Email Archana.Patel@childrens.harvard.edu  
 
Phillip C. Thesing, DO DTMH 
Research Coordinator & Clinician 
Neurology Research Office 
UTH Lusaka Children’s Hospital 
Paediatric Annex 
Private Bag RW1X 


 
Aggressive Antipyretics for Fever 
 
 
Control in CNS Malaria 
 
 
Version 5.3 
21 Jan 2021 
Page 5 of 33 
Ridgeway 
Lusaka, Zambia 
Cell +260-962121455 
Email Phillip_Thesing@urmc.rochester.edu 
Skype: phillip.thesing  
 
University of Rochester Study Co-coordinator 
Ifunanya F. Dallah, BA 
University of Rochester 
Center for Health & Technology 
265 Crittenden Blvd 
CU 420694 
Rochester, NY 14642-0694, USA 
Office: +1-5852752791 
Cell: +1-3014123291 
Email: Ifunanya_Dallah@URMC.Rochester.edu 
SkypeID: Ifunanya.dallah 
 
Ivy Mulwani Makulu 
Site Administrator (Zambia) 
UTH Neurology Research Office 
Paediatric Annex 
Private Bag RW1X 
Ridgeway 
Lusaka, Zambia 
Cell +260-974795275/+260-950644493 
Email chase2uth@yahoo.com    
 
Authors’ contributions: 
GB conceived of the study. GB, KS, and MacM initiated the study design. IM and PT will help with study 
implementation. Mike M will complete the initial statistical analysis. All authors contributed to refinement 
of the study protocol. 
 
5(b) Trial sponsor  
 
 
University of Rochester,  
Departments of Neurology and Public Health,  
Center for Health & Technology 
265 Crittenden Blvd 
CU 420694 
Rochester, NY 14642-0694 
USA 
 
5(c) Role of study sponsor and funders 
 
The funding source had no role in the design of this study and will not have any role during its 
execution, analyses, interpretation of the data, or decision to submit the results. 
 
5(d) Composition of Advisory Committee1, Local Study Monitor and Data Safety Monitoring 
Board 
 
Terrie E. Taylor, DO 
 
1 Advisory Committee include DSMB, Pediatric Research Ward Directors, and Heads of Pediatrics Departments at both 
study sites. 


 
Aggressive Antipyretics for Fever 
 
 
Control in CNS Malaria 
 
 
Version 5.3 
21 Jan 2021 
Page 6 of 33 
Director-Blantyre Malaria Project 
Box 30096 
Blantyre 3, Malawi 
Cell +265-999969220 
Email ttmalawi@msu.edu  
 
Macpherson Mallewa, MBBS MRCP MRCPCh DTMH PhD  
Co-Investigator 
Consultant Paediatric Neurologist/ 
Senior Lecturer/Deputy Head-Department of Paediatrics 
Core Paediatrician-MLW 
College of Medicine Malawi-Liverpool-Wellcome Trust Clinical Research Programme 
P.O. Box 30096, Chichiri  
Blantyre 3, Malawi 
Tele +265-1876444 
Tele +265-9995835083 
Email mmallewa@mlw.medcol.mw  
 
Josephine Langton, MBChB, MRCPCH 
Academic Head of Department, Paediatrics and Child Health  
Queen Elizabeth Central Hospital 
Chipitala Ave., Chichiri 
Blantyre 3, Malawi 
Tele +265-993630543 
Email joelangton@doctors.org.uk  
 
Local Study Monitors 
 
Zambia: 
John Musuku, MBBS, MBChB 
Senior Medical Superintendent 
UTH Lusaka Children’s Hospital 
Nationalist Ave 
Lusaka, Zambia 
Tele +260-966766052 
Email jmusuku2001@yahoo.co.uk  
 
Dr. Mbinga Mbinga 
Senior Medical Superintendent 
Chipata Central Hospital 
P.O. Box 510119 
Chipata, Zambia 
Tele +260-216-221427/-223093/-223083 
Fax +260-216-222414 
Email dr.mbinga@gmail.com  
 
Dr. Nyakulira Elita Kandiwo (alternate/backup) 
EPHO 
P.O. Box 510023 
Chipata, Zambia 
Phone: (+260) 977-541-336 / 966-531-336 
Email: nyakukandiwo@gmail.com  
 
 
Malawi: 
Neema Mtunthama Toto, BSc Nursing, MSc Clinical Trials 
Cryptofaz Programme Manager 
Malawi Liverpool Wellcome Trust  


 
Aggressive Antipyretics for Fever 
 
 
Control in CNS Malaria 
 
 
Version 5.3 
21 Jan 2021 
Page 7 of 33 
P.O. Box 30096 
Blantyre 3 
Malawi 
Cell: +265-999981451 
Email: ntoto@mlw.mw 
Skype: Neema Toto 
 
 
George Chagaluka, B. Surgery & Medicine,  
Specialist in Pediatrics & Child Health, Oncology Fellow 
Department of Pediatrics & Child Health 
Pediatric Dept., College of Medicine 
Private Bag 360, Blantyre 3 
Malawi 
Cell: +265-998-108-968 
Email: gchagaluka@medcol.mw , gchagaluka@gmail.com  
Skype: georgechagaluka 
 
DSMB  
 
Professor Quique Bassat (Chair) 
Barcelona Institute for Global Health 
Rossello 132 
08036 Barcelona, Spain 
Cell +34609556300 
Email quique.bassat@isglobal.org 
 
 
Chandy C. John, MD 
Indiana University, Department of Microbiology & Immunology 
635 Barnhill Drive, MS 420 
 
Indianapolis, IN 46202 
Tele +1-3172789290 
Cell +1-6128399307 
Email chjohn@iu.edu  
 
Dr. Richard Idro 
Mulago Hospital, Makerere University School of Medicine 
PO Box 7072 
Kampala  
Uganda 
Cell +256-414531875 
Email ridro1@gmail.com 
 
Joseph C. Gardiner, PhD 
University Distinguished Professor 
Associate Chair, Department of Epidemiology and Biostatistics 
Professor, Biostatistics & Epidemiology 
909 Fee Road, West Fee Hall, Room B629  
East Lansing, MI 48824-1315 
USA 
Tele +1-517-884-3967 
Fax +1-517-432-1130 
East Lansing, MI 48824-1315 
USA 
Email jgardiner@epi.msu.edu  
 
Prof. Malcolm E. Molyneux 
Emeritus Professor  
Liverpool School of Tropical Medicine 


 
Aggressive Antipyretics for Fever 
 
 
Control in CNS Malaria 
 
 
Version 5.3 
21 Jan 2021 
Page 8 of 33 
5 Pembroke Place, Liverpool, UK 
Tel (+44) 151-9243184 
Mobile (+44) 7810-603669 
Email mmolyneux999@gmail.com  
 
 


 
Aggressive Antipyretics for Fever 
 
 
Control in CNS Malaria 
 
 
Version 5.3 
21 Jan 2021 
Page 9 of 33 
 
6. Background and rationale 
6(a) Description of research question 
 
Significance 
Neurologic Sequelae Following Severe Malaria in Childhood 
 
Despite eradication measures, ~200 million malaria cases occurred in 2013 with ~500,000 
malarial deaths, primarily in African children(1). Neurologic sequelae occur in 1/3rd of survivors of CNS 
malaria, meaning parasitemia and neurologic symptoms including impaired consciousness and/or 
seizures (2-5). Newer antimalarial medications rapidly clear peripheral parasitemia and improve 
survival, but mortality remains high at 12-25% with no associated decline in post-malaria neurologic 
injury (6). Past studies have identified neurologic deficits at discharge in 9-18% of CNS malaria 
survivors with additional sequelae, such as epilepsy, becoming evident with longer term follow-up (2, 7-
13). We conducted a prospective cohort study (BMPES) of children with the most severe form of CNS 
malaria—cerebral malaria (CM). CM is defined as unarousable coma (persisting for at least 30 
minutes after any seizure), parasitemia and no other coma etiology(14). When followed for an average 
of 77 weeks, 32% of BMPES children experienced neurologic sequelae including epilepsy (9%), 
behavioral problems (11%) and new neurodisabilities (23%)(2). Data from studies in other malaria-
endemic African countries indicate that neurologic sequelae are not unique to children with CM. Children 
with “CNS malaria”, meaning malaria-associated seizures or impaired consciousness without deep coma 
also experience high rates of sequelae. 
 
Table 1: A Review of Neurologic Outcomes after CNS Malaria 
COUNTRY 
INCLUSION CRITERIA 
ASSOCIATED NEUROLOGIC OUTCOME 
Uganda(15, 16) 
Children 5-12 years. Convulsions for > 15 minutes, 
repeated seizures in 24 hours based upon parental or 
healthcare staff report, abnormal level of consciousness 
(GCS≤14), or coma. Only 9/62 had cerebral malaria. 
Early problems with behavior and longer term 
follow-up identified poor academic 
performance and cognitive problems. 
Kenya(17), (18) 
Children with complicated seizures during malaria (not 
cerebral malaria) 
Long term problems with executive function 
compared to unexposed children  
Kenya(5) 
Children with malaria and seizures (M/S) compared to 
children with cerebral malaria(CM) 
Comparable rates of epilepsy during follow-
up and both exceeded the rates in 
unexposed  
Kenya(4) 
Children with malaria and seizures (M/S) compared to 
children with cerebral malaria(CM) 
24% of M/S and CM kids experienced 
neurologic sequelae during follow-up though 
CM kids were more likely to have multiple 
deficits.  
Kenya(17) 
Children with M/S (and not CM) 
Language and behavioral problems at follow-
up 
Zambia(19) 
Children 6 months to 6 years. Fever and seizures with 
81% of cohort having malarial fever but <1% meeting 
criteria for cerebral malaria. Complicated seizures (focal, 
recurrent in 24 hours and prolonged) were common. 
11.2% of children with complicated seizures 
developed epilepsy during follow-up and 15% 
had new neurodevelopmental problems at 
discharge or during follow-up 
 
Fever as a Risk Factor for Malaria-Associated Brain Injury (Scientific Premise) 
 
In BMPES, acute symptomatic seizures and a higher maximum temperature (Tmax) during the 
acute infection were associated with a greater risk of post-malaria neurologic sequelae. Children who 
developed epilepsy had a mean Tmax of 39.4°C vs. 38.5°C in those who did not develop epilepsy 
(absolute difference of 0.9°C; p=0.01). In addition, a higher Tmax predicted subsequent behavioral 
disorders (39.2°C vs. 38.7°C; absolute difference 0.5°C; p=0.04). These data are biologically consistent 
with the substantial body of evidence that fevers contribute to secondary neurologic injury in the setting 
of stroke, meningitis, anoxia, hypoxia, and trauma (20-24). In the U.S., induced hypothermia is now 
standard-of-care for post-anoxic(25) and neonatal hypoxic-ischemic encephalopathy(26-29) and fever-
reduction is an important aspect of neurocritical care(30-33). Malaria-induced fevers can be extremely 
high. Fifteen percent of the BMPES cohort experienced at least one temperature of ≥ 40.0°C (104.0°F). 
The age-related susceptibility to pediatric malaria substantially overlaps with the age-related 
phenomena of febrile seizures. Malarial seizures are often complex, multifocal, and prolonged with 
status epilepticus being common (2, 19, 34, 35).  See Table 2 for potential mechanisms of fever-
induced injury in CNS malaria. 
 


 
Aggressive Antipyretics for Fever 
 
 
Control in CNS Malaria 
 
 
Version 5.3 
21 Jan 2021 
Page 10 of 33 
Standard-of-Care for Malarial Fevers 
 
Despite substantial evidence for the deleterious effects of fever after brain injury, the World 
Health Organization’s (WHO) Malaria Care Guidelines recommend fever treatment only for rectal T ≥ 
38.5°C(36). Since malaria-associated fevers escalate rapidly, treatment based upon this threshold 
means many children develop significant hyperpyrexia prior to initiating fever-reduction therapy. In the 
BMPES cohort, among 52 children who were afebrile at the time of admission the mean Tmax during 
hospitalization was 39.0°C and 13/52 (25%) had a post-admission fever of ≥39.0°C based upon Q2 
hourly evaluations. In most malaria care settings, vital signs are only assessed every 6-12 hours, so 
adherence to WHO Guidelines inevitably result in children with CNS malaria developing and 
maintaining high fevers for some hours before antipyretics are initiated.  
While the neurologist accustomed to aggressive fever management in the neurocritical care unit 
may find this approach to fever management in pediatric malaria baffling, WHO guidelines and clinical 
practice patterns are likely predicated upon two factors—first, the well-described dearth of neurologic 
expertise in malaria-endemic regions(37) and secondly, some evidence suggesting that malarial fevers 
may be desirable. In vitro studies have shown that febrile temperatures inhibit parasite growth with the 
conclusion being that “long, high fevers during malaria may be beneficial for parasite clearance”(38) 
and a clinical trial of antipyretics for malarial fevers found that peripheral parasite clearance time was 
delayed in children who received acetaminophen(39). 
 
 
Table 2: Potential Mechanisms of Fever-Induced Brain Injury in CNS Malaria 
MECHANISM OF  
FEVER-INDUCED  
INJURY 
RELATIONSHIP TO CNS MALARIA PATHOPHYSIOLOGY 
↑ proinflammatory 
cytokine cascade 
(1) cerebral malaria cerebrospinal fluid (CSF) CSF exhibits high levels of inflammatory cytokines 
including interleukin (IL)-6, CXCL-8/IL-8, granulocyte- colony stimulating factor (G-CSF), tumor necrosis 
factor- alpha (TNF-alpha), and IL-1 receptor antagonists(40) 
(2) High TNF alpha levels are associated with later cognitive impairment(41) 
↑ excitoxicity 
including 
↑intracellular 
glutamate 
The high rates of age-dependent seizures in cerebral malaria are thought to be mediated by excitotoxic 
neurotransmitters especially glutamate (42, 43). Glutamate diffusion occurs with subsequent increase in 
glutamate-induced damage 
Acceleration of free 
radical 
production 
(1) Free radicals are also generated by the parasite. Excessive production can overwhelm glutathione 
metabolism(44) 
(2) Reactive oxygen intermediates may be important for parasite clearance in uncomplicated malaria(45) 
(3) Animal models indicate free radical production hastens tissue damage in cerebral malaria(46) 
Fever potentiates 
sensitivity of 
neurons to 
CSF in Malawian children with CM has elevated levels of the excitotoxin quinolinic acid. Higher levels of 
this excitotoxin are seen in CM children with acute seizures and higher levels are also associated with 
CM mortality(40),(43) 
↑cerebral metabolic 
rate 
(1) In CM focal, prolonged seizures +/- hypoglycemia +/- local ischemia from sequestration-induced 
sludging +/- systemic hypoxia +/- anemia makes brain tissue more susceptible to injury from primary 
energy failure associated with the increased metabolic rate from fevers(35) 
(2) Where auto-regulatory dysfunction occurs, an increased metabolic rates causes increased cerebral 
blood flow and increased intracranial pressure. Brain swelling has recently been shown to be the key 
structural predictor of mortality in pediatric CM based upon MRI(47) 
Increased 
sequestration(48) 
Increased rosette formation, a temperature dependent phenomena, results in enhanced CNS parasite 
sequestration, increased microvascular obstruction and increased ischemia and edema. 
 
New Insights into Parasite Behavior and Improved Methods for Measuring Parasite Burden 
 
In vitro, uninfected red blood cells (RBCs) stick to those infected with trophozoites and schizonts 
of P. falciparum forming rosettes which are thought to play an important role in sequestration and 
microvascular obstruction. Studies have shown that rosette formation increases from 37.0 to 40.0°C 
(48). This temperature-dependent, PfEMP-1 mediated effect doubles RBC cytoadherence and may 
explain the delayed peripheral parasite clearance time associated with antipyretic use (39). 
Essentially, since lowering temperatures may attenuate cytoadherence, peripheral parasite 
counts may transiently increase as sequestered parasites are liberated into the bloodstream. 
This may actually be a desirable effect if by doing so antipyretics improve cerebral blood flow at 
the capillary-level and reduce sequestration. Parasitized erythrocytes have also been shown to lose 
their flexibility at temperatures over 37.0°C especially in the late trophozoite and schizont phase, which 
likely further exacerbates sequestration (49). 
Histidine Rich Protein II (HRP2), a Plasmodium-specific protein in patient plasma, may facilitate 
quantification of whole-body parasite burden. Recent studies led by Dr. Seydel are supportive of the 


 
Aggressive Antipyretics for Fever 
 
 
Control in CNS Malaria 
 
 
Version 5.3 
21 Jan 2021 
Page 11 of 33 
supposition that sequestered parasites, not those circulating in the peripheral blood, are the primary 
contributors to severe malaria. They found that mean plasma HRP2 concentrations early in the malaria 
infection predict progression to CM, even among children receiving treatment(50). Higher plasma levels 
of HRP2 are also associated with CNS parasite sequestration based upon autopsy findings and 
bedside retinal assessments with quantitative HRP2 levels of ≥1700ng/ml providing 98% sensitivity and 
98% specificity for identifying CNS parasite sequestration (area under the ROC curve 0.98)(51). As 
such, HRP2 levels provide excellent proxy data for establishing CNS parasite sequestration even in 
conscious, acutely ill children in whom funduscopy is problematic. 
 
Study Rationale  
 
Studies of other pediatric infections have shown that combination therapy with standard 
antipyretics can result in reduced fevers, but whether this is true for malaria-associated fevers is unclear. 
Although antipyretic use with a single agent in one malaria study was associated with prolonged 
peripheral parasitemia, fever clearance time was not significantly different (32 hours in the antipyretic 
treated group vs. 43 hours in routine care; p=0.176)(39). Limited fever reduction benefits from single 
antipyretic agents in malaria have been shown in other studies(52). A randomized controlled trial of 
acetaminophen (without a loading dose) vs. ibuprofen found an ibuprofen advantage only at 4.5 hours 
post treatment(53). A controlled trial of acetaminophen vs. placebo for uncomplicated malaria found no 
differences in mean temperature, but 6/171 children receiving placebo required admission for febrile 
seizures compared to 2/167 on acetaminophen (54). Antipyretic efficacy has been shown in some 
studies--acetaminophen is more effective in malaria fever reduction than tepid sponging(55). No malaria 
studies to date have evaluated the impact of prophylactic treatment to prevent fevers or 
interventions using two antipyretics with different mechanisms of action.  
Acetaminophen’s mechanism of action is not fully understood, but it is a potent inhibitor of 
prostaglandin production in the CNS with minimal anti-inflammatory effects(56). Recent studies suggest 
that it inhibits the peroxidase functions of COX-1 and COX-2 with selectivity for the inhibition of 
prostaglandin synthesis (57). In children with non-malarial fevers and a rectal temperature of >39.0°C, 
15 mg/kg of acetaminophen resulted in a decrease of 1.07-1.98°C(58), which is greater than the 
temperature difference associated with better neurological outcomes in the BMPES study. The primary 
safety concern with acetaminophen use is the hepatotoxicity that can occur when the recommended 
dosage is exceeded. Ibuprofen is a non-selective COX inhibitor, inhibiting both COX-1 and COX-2. The 
analgesic, antipyretic, and anti-inflammatory activity of ibuprofen is achieved mainly through inhibition 
of COX-2, whereas inhibition of COX-1 impacts platelet aggregation and likely mediates gastrointestinal 
side effects (59). By 1991, some estimates indicated that over 250 million children had received 
ibuprofen with very few serious adverse events reported (60, 61). The most common ibuprofen side 
effects include gastritis, impaired platelet function and decreased urinary excretion of sodium. Among 
non-steroidal anti-inflammatories, ibuprofen is the least likely to cause gastrointestinal bleeding. Studies 
have shown both acetaminophen and ibuprofen to be safe in children when used individually(62, 63) 
and in combination(64). Both agents have been shown to be generally safe and effective for fever 
reduction in children (65-67). Studies in children with non-malarial fevers have found some additional 
fever-reduction benefit when the two drugs are used together(64). A Malawi-based study of children 
with uncomplicated malaria comparing acetaminophen and ibuprofen found no difference in fever 
resolution time and no serious adverse effects from either treatment were identified(68). 
Acetaminophen and ibuprofen are already approved for fever reduction in the dosage outlined 
for this planned intervention for use in children age 2-11 years by the appropriate regulatory 
agencies (the Pharmacy, Medicines and Poisons Board in Malawi and Zambia Medicines 
Regulatory Authority) as well as the US Food and Drug Administration. 
The rationale for this clinical trial is based upon (1) unmet clinical need in terms of the imperative 
to decrease the neurologic injury and sequelae that occur in ~250,000 malaria survivors each year, (2) 
previous epidemiologic data indicating that higher Tmax is associated with neurologic sequelae in CNS 
malaria, (3) the very plausible biological mechanisms of malarial fever-related secondary brain injury 
detailed in Table 2, (4) in vivo and in vitro data on temperature dependent parasite behavior and whole 
body parasite burden suggesting that findings from previous research linking fever reduction to slowed 
parasite clearance may be erroneous. 
 
Innovation 
 
Despite substantial evidence that hyperthermia in the setting of acute CNS injury generally 
worsens neurologic damage as well as observational data in pediatric CNS malaria showing the same 


 
Aggressive Antipyretics for Fever 
 
 
Control in CNS Malaria 
 
 
Version 5.3 
21 Jan 2021 
Page 12 of 33 
association, malaria care guidelines today recommend a single antipyretic agent and treatment 
initiation only after a significant fever (T ≥ 38.5ºC) occurs. The clinical trial proposed here seeks to 
challenge this practice paradigm by evaluating the fever-reduction efficacy of more aggressive 
antipyretic use while also taking advantage of a relatively new method for quantifying total parasite 
burden (HRP2) to further characterize malaria severity and elucidate the impact of antipyretics on 
parasite sequestration and clearance. This study will also assess the efficacy of aggressive antipyretic 
use in deterring acute symptomatic seizures during the malaria infection. The trial is novel in the 
provision of prophylactic treatment, the proposed use of combining two agents, and the select patient 
population—namely children with CNS malaria rather than uncomplicated malaria as were included in 
prior antipyretic malaria trials. Our “go” criterion will be met if we reject the null hypothesis of no 
treatment effect (i.e., no reduction in mean Tmax in the aggressive antipyretics group). If the true 
treatment effect is a reduction of at least -0.5ºC, we will have a 90% chance of detecting significance of 
the treatment effect. If the ‘go’ criterion is met, the phase III study to follow would be innovative in that it 
would entail a trial of aggressive antipyretics with the goal of normothermia rather than induced 
hypothermia as a neuroprotective intervention after CNS injury. 
 
Preliminary Data 
Capacity to Conduct Clinical Trials and Capture Delayed Outcomes  
Our prior outcome studies of severe malaria (2, 19) has provided us with the experience of 
(successfully) negotiating the regulatory requirements and compliance challenges of conducting an 
NIH-funded clinical trial in the African setting has provided us with the experience of (successfully) 
negotiating the regulatory requirements and compliance challenges of conducting an NIH-funded 
clinical trial in the African setting.  
 
Further Insights into the Role Fever Plays in the Pathophysiology of Neurologic Injury in CNS Malaria 
 
IS FEVER INDEPENDENTLY ASSOCIATED WITH ADVERSE NEUROLOGIC OUTCOMES? Children with CNS 
malaria are of an age to be susceptible to febrile seizures and acute malarial seizures are a well-
established risk factor for neurologic sequelae in malaria survivors. To evaluate whether temperature 
independently affects neurologic outcomes in CNS malaria, we used the BMPES data to examine the 
relationship between Tmax and adverse neurologic outcomes in a regression model that adjusted for 
the presence/absence of seizures during the acute admission. After controlling for acute seizures, a 
higher Tmax remained associated with adverse neurologic sequelae during follow-up (p=0.029).  
 
DOES THE RELATIONSHIP BETWEEN FEVER AND ADVERSE NEUROLOGIC OUTCOME HOLD TRUE FOR CHILDREN 
WITH CNS MALARIA MORE BROADLY DEFINED? The BMPES study, which identified a higher Tmax as being 
a risk factor for neurologic sequelae in CNS malaria, only included children with retinopathy positive 
CM(2). Although children with the more broadly defined CNS malaria experience similar rates of 
neurologic injury evident after recovery (detailed in Table 1 above), little is known or published about 
the impact of fever on outcomes in this broader population. To examine the effects of fever on a 
broader population of children with malaria, we compared Tmax in retinopathy negative children with 
and without neurologic sequelae who were enrolled during the BMPES study. The clinical 
characteristics(69), neurologic outcomes(70) and MRI findings(71) of these retinopathy negative 
children have been previously described. Among 35 retinopathy negative children, the mean Tmax 
in children with neurologic sequelae was 39.2ºC vs. 38.7ºC in those without sequelae—a finding 
very consistent with the difference in mean Tmax found in the retinopathy positive BMPES 
cohort suggesting that fever likely plays a role in neurologic injury across the broader spectrum 
of CNS malaria. 
 
WHAT IS THE PATHOPHYSIOLOGIC BASIS FOR FEVER-MEDIATED SECONDARY BRAIN INJURY? HOW CAN WE 
BEST CAPTURE THIS EXPOSURE? Based upon numerous epidemiological studies (20-24) (25-29)(30-
33)(30-33)￼(72) data from malaria experiments conducted by White et al. led them to conclude that 
keeping the temperature at 37.0°C will delay cytoadherence by 3 hours and allow up to 25% of the ring 
parasites to be removed before sequestration (48) other aspect of fever exposure. Fortunately, the 
0.5ºC difference in mean Tmax in children with vs. without sequelae in the BMPES study does offer 
some insights into what constitutes a clinically meaningful difference in Tmax. To further explore 
whether Tmax is the most sensitive measure for predicting fever-associated neurologic sequelae from 
malaria, we returned to the BMPES study data and examined the association between adverse 


 
Aggressive Antipyretics for Fever 
 
 
Control in CNS Malaria 
 
 
Version 5.3 
21 Jan 2021 
Page 13 of 33 
neurologic outcome and area under the fever-time curve based upon Q2 hourly assessments using a 
fever threshold of 37.0ºC and a threshold of 37.5ºC. Unlike Tmax, these alternate measures of 
temperature exposure were not associated with adverse neurologic outcomes, so our primary 
outcome remains Tmax. Unlike Tmax, these alternate measures of temperature exposure were 
not associated with adverse neurologic outcomes, so our primary outcome remains Tmax. 
 
HRP2 Studies 
 
 
7. Objectives  
 
7.1 Hypothesis 
We hypothesize that children who receive aggressive antipyretic therapy will have: 
(i) A lower mean Tmax using computer-based continuous temperature monitoring 
(ii) Decreased acute symptomatic seizures during the 72 hour treatment period 
(iii) A lower incidence of long term neurologic sequelae. This will be assessed in the more definitive 
study to follow if we meet our “go” criterion—meaning we reject the null hypothesis of no treatment 
effect with findings of a lower mean Tmax in the aggressive antipyretic treatment group compared to 
usual care. 
7.2 Primary objectives 
 
7.2.1 To conduct a randomized, double-blind, placebo controlled trial of aggressive antipyretic therapy 
to reduce Tmax in pediatric CNS malaria and evaluate the “proof-of-concept” for potential 
neuroprotective efficacy. Children admitted with CNS malaria, defined as malaria with impaired 
consciousness and/or seizures, will be randomized to usual care (15 mg/kg acetaminophen Q6 hours 
as needed for ≥ 38.5ºC) vs. aggressive antipyretic therapy with prophylactic acetaminophen (30 mg/kg 
load followed by 15 mg/kg Q6 hours) PLUS ibuprofen (10 mg/kg Q6 hours) from time 0 to hour 72, the 
timeframe in which most children with malaria will defervesce 
 
7.3 Secondary objectives 
 
7.3.1 To evaluate the safety of aggressive antipyretic therapy. After enrollment, serial assessments to 
identify incident hypoglycemia, bleeding/clotting problems, renal insufficiency, and/or hepatic 
dysfunction will be undertaken. Local Study Monitors will review adverse events for individual 
participants in real time. Interim analyses will be conducted annually with explicit stopping rules based 
upon mortality. 
  
7.3.2 To assess the effect of aggressive antipyretic therapy on parasite sequestration and parasite 
clearance, we will evaluate host parasite burden through Q6 hourly quantitative parasite counts as well 
as HRP2 quantitation. We hypothesize that fever treatment will reduce sequestration resulting in lower 
HRP2 levels based upon area under the curve during the 72 hour treatment period and that an 
associated transient paradoxical increase in peripheral parasitemia with a higher proportion of older 
parasites will be seen as centrally sequestered parasitized red blood cells are released. 
Our studies of HRP2 levels in Malawian children 
have supported the importance of quantifying the 
parasite burden through means other than a 
peripheral blood smear. HRP2 levels in the 
periphery are affected by multiple variables, 
including level of sequestration and rate of parasite 
clearance post-treatment. In a preliminary 
experiment we measured Q6 hour HRP2 levels 
post-treatment and found that marked differences 
occur despite identical treatment. We therefore will 
measure HRP2 levels every 6 hours in both arms 
of the trial with the hypothesis that in the 
aggressive antipyretic arm sequestration will be 
reversed and thus area under the concentration-
time curve of HRP2 levels will decrease. 


 
Aggressive Antipyretics for Fever 
 
 
Control in CNS Malaria 
 
 
Version 5.3 
21 Jan 2021 
Page 14 of 33 
8. Trial design 
 
The trial will be randomized, double-blind, placebo-controlled trial of aggressive antipyretic therapy with 
the primary outcome being the maximum temperature occurring in the 72 hours after presentation with 
acute malaria. Children with malaria and neurologic symptomatology (either cerebral malaria or CNS 
malaria) will be randomized to receive aggressive antipyretic therapy with scheduled acetaminophen 
starting with a 30mg/kg load following by 15mg/kg Q6 hourly PLUS ibuprofen 15mg/kg Q6 hourly vs. 
usual care. Usual care is 15mg/kg of acetaminophen Q6 hourly as needed for a temperature of 
≥38.5°C. A total of 284 children (142 in each study arm) will be enrolled. 
Methods: Participants, Interventions, and Outcomes 
9. Study setting 
 
The study will be carried out in three settings: the Pediatric Research Ward (PRW) at Queen Elizabeth 
Hospital in Blantyre, Malawi; the Pediatric Intensive Care Ward (PICU) at University Teaching Hospital 
in Lusaka, Zambia; the High Acuity Section within the Pediatric Ward at Chipata Central Hospital, 
Chipata, Zambia.  
 
10. Eligibility criteria 
 
Parents or guardians must provide written informed consent in their local language prior to any 
procedures or treatments taking place. 
 
10.1 Inclusion Criteria 
10.1.1 Age 2-11 years (24 to 132 months) 
10.1.2 Evidence of P. falciparum malaria infection by peripheral blood smear or rapid diagnostic test 
10.1.3 CNS symptoms associated with malaria. CEREBRAL MALARIA:  Impaired consciousness with a 
Blantyre Coma Score (BCS)(73) ≤2 in children under 5 years or a Glasgow Coma score (GCS) ≤10 in 
children ≥5 years OR CNS MALARIA: Complicated seizure(s), meaning prolonged (>15 minutes), focal or 
multiple; or impaired consciousness or other evidence of impaired consciousness (confusion, delirium) 
without frank coma (BCS>2, GCS =11-14)  
10.2 Exclusion Criteria 
10.2.1 Circulatory failure (cold extremities, capillary refill > 3 seconds, sunken eyes, ↓ skin turgor) 
10.2.2 Vomiting in the past 2 hours 
10.2.3 Serum Cr > 1.2 mg/dL 
10.2.4 A history of liver disease 
10.2.5 Jaundice or a total bilirubin of >3.0mg/dL 
10.2.6 A history of gastric ulcers or gastrointestinal bleeding 
10.2.7 A history of thrombocytopenia or other primary hematologic disorder 
10.2.8 Petechiae or other clinical indications of bleeding abnormalities  
10.2.9 A known allergy to ibuprofen, acetaminophen, aspirin or any non-steroidal medication 
*10.2.10 Any contraindication for nasogastric tube (NGT) placement and/or delivery of enteral 
medications  
 
10.3 Vulnerable Population 
Children with CNS malaria in Africa are a vulnerable population. They are targeted for inclusion in this 
study because they are the population who suffers from CNS malaria. Measures will be taken to 
safeguard their rights and welfare including a thorough informed consent process (Sec. 26 of protocol) 
and a detailed data and safety monitoring plan (Sec 21 of protocol). Staff who consent study subjects 
are local healthcare workers fluent in the local language. 
 


 
Aggressive Antipyretics for Fever 
 
 
Control in CNS Malaria 
 
 
Version 5.3 
21 Jan 2021 
Page 15 of 33 
11. Interventions 
11(a) Interventions 
 
Study Intervention 
 
11.a.1 Intervention arm-scheduled dosing every 6 hours with acetaminophen (30mg/kg p.o. load then 
15mg/kg Q6 hours) and ibuprofen (10mg/kg Q6 hourly), starting at enrollment (hour 00) and continuing 
through hour 72 including a final dose at hour 72.  
 
11.a.2 Usual care arm-acetaminophen 15mg/kg Q6 hourly as needed for temperature ≥ 38.5°C based 
upon axillary temperatures taken in the course of routine clinical care (starting at enrollment (hour 00) 
and continuing through hour 72 including a final dose at hour 72) 
.1   
 
 
 
11.a.3 Children who have received acetaminophen in the 24 hours prior to 
presentation,  based upon the available medical record or report from the parent or guardian, 
will not be given a loading dose of acetaminophen. Instead, they will be commenced on the 
maintenance dose of 15mg/kg Q6 hourly. 11(b) Criteria for discontinuing or altering 
interventions 
 
 
 
 Table 3. Plan for Monitoring and Discontinuation 
ADVERSE EVENT 
MONITORING 
PATIENT MANAGEMENT 
INTERIM ANALYSIS THAT MAY 
INFORM DISCONTINUATION 
Vomiting2 
Clinical monitoring  
Re-dose if within 30 minutes of  
Treatment. Stop aggressive  
antipyretics if grade 2 aspiration  
occurs 
Compare % vomiting 
NGT-related injury 
Clinical monitoring 
Withdraw from study if drug  
delivery requires NGT 
----------------------------------- 
Recurrent 
hypoglycemia 
Glucose checks Q6 hourly  
if BCS<5 or seizure 
Treat per ward protocols  
Compare proportion  
as well as # of events  
Lactic acidosis (above 
5.0 mmol/L) at or after 
24 hours of treatment  
Daily until intervention 
completed 
  Can be assessed more 
frequently at clincian’s discretion 
Compare hours with lactic 
acidosis and max. lactate  
Hepatic dysfunction 
with 
bilirubin increasing 
from 
baseline  
Clinical monitoring 
Daily total bilirubin  
Stop treatment if jaundice 
develops or bilirubin increases 
by >5mg/dL from baseline  
Compare max increase in  
bilirubin level from baseline  
Renal insufficiency 
with 
Increased Cr from  
baseline 
Clinical monitoring 
Daily serum creatinine  
 
Stop for clinical evidence of  
Renal insufficiency (poor urine 
output, peripheral edema) or  
>0.5mg/dL increase creatinine 
from baseline or a doubling of 
the baseline creatinine 
Compare max. creatinine & 
Proportion of subjects with  
Increase of ≥0.5 mg/dL 
Anemia and 
transfusion3 
 
6-hourly packed cell volume 
(Malawi: once two consecutive 
negative malaria smears, no 
further PCV will be done; 
Zambia: through hr-72) 
Transfuse, as needed.  
Compare % requiring 
transfusion  
Occult blood loss  
 
Daily urine dip for blood and  
Stool Hemoccult 
No action for occult blood loss.  
Compare % with occult  
blood loss detected 
Clinical evidence of 
Thrombocytopenia or 
Bleeding  
Daily check for purpura, 
Oozing from IV sites, 
petechiae, 
Or other bleeding 
Stop for any clinical evidence of  
Thrombocytopenia/bleeding 
Compare % with 
clinical evidence of 
thrombocytopenia/bleeding 
Prolonged parasitemia 
----------------------------------------- 
------------------------------------------- 
Mean hours for parasite  
clearance 
 
2 For grading purposes of vomiting as an AE: grade 1=no change in oxygen saturation and no evidence of aspiration, grade 2=suspected 
aspiration but no change in oxygen saturation, grade 3=oxygen saturation decrease that responds to immediate treatment and grade 
4=oxygen saturation decrease which does not respond to immediate treatment 
3 Expected with severe malaria so not AE per se but will compare rates in Interim analysis 


 
Aggressive Antipyretics for Fever 
 
 
Control in CNS Malaria 
 
 
Version 5.3 
21 Jan 2021 
Page 16 of 33 
 
 
Children will be withdrawn from the study if requested by a parent or clinician caring for the patient or 
recommended by the Local Study Monitor (LSM) or DSMB.  
 
11(c) Strategies to improve adherence 
 
All doses will be directly administered by a study-trained nurse. The administering ward nurse will 
directly observe the oral intake of the medication and document oral adherence. If vomiting occurs with 
30 minutes of oral administration, a repeat dose will be given and documentation of the event made. 
 
 
11(d) Relevant concomitant care 
 
Concomitant Treatment and Investigations 
All treatments routinely used in the acute care of children with severe malaria will be provided (75). 
These include antimalarials, anticonvulsants, and blood transfusions. The duration and characteristics 
of all clinical seizures are documented in a bedside “fitting chart”. Due to the significant risk of 
subclinical seizures in comatose children with malaria (2), a daily, routine, 30-minute EEG will be 
completed in any child with a BCS≤4 or GCS≤10. When necessary, nasogastric tube (NGT) placement 
will be undertaken by experienced ward/unit nurses. The NGT will be removed and oral administration 
resumed as soon as the child is able to swallow.  
 
12. Outcomes 
12.1 Primary outcome measures 
 
12.1.1 Maximum temperature (TMAX). TMAX will be defined as the highest temperature during the study 
duration (72 hours) in degrees Celsius recorded by a continuous temperature monitor. Regardless of 
treatment allocation, temperature will be continuously assessed for 72 hours using a non-invasive, 
accurate temperature monitoring system that continuously measures patient temperature using an 
external temperature sensor placed in the axilla. The continuous temperature display will be concealed 
from nursing staff responsible for measuring temperatures for clinical care and delivering rescue fever 
treatment based upon the protocol. Temperature data will be captured locally on a device and also 
transmitted via email to a dedicated study account. The continuous monitoring device is not MR 
compatible. If Tmax is a clinical temperature obtained when continuous monitoring data was not 
available, the clinical Tmax will be used as the primary outcome.  
12.2 Secondary outcome measures 
 
12.2.1 SEIZURES will be assessed for occurrence and severity, from t=0 to t=72 hours based upon 
“Fitting Charts” and a daily routine EEG in comatose (BCS≤4 and GCS≤10) children. The daily EEG will 
be reviewed by the neurologist covering the PRW or PICU Neurodiagnostic Service. Seizure outcome 
has three categories—no seizures, a single brief (<15 minute) seizure, and multiple or prolonged 
(>15 minutes) seizures. These seizure categories are clinically relevant and correspond to risk factors 
for subsequent neurologic sequelae in our previous Zambia-based prospective cohort study of fevers 
and seizures (19).  
 
12.2.2 HRP2 (i.e., total body parasite burden) is the quantitative level reported as ng/ml in plasma. 
Samples for HRP2 determination will be obtained Q6 hourly via finger prick. Levels will be determined 
by ELISA and will not be available in real time.  
 
 
12.2.3 QUANTITATIVE PARASITE COUNT (qPC, peripheral parasite burden) is the number of parasites per 
microliter of blood based upon standard laboratory measures and obtained Q6 hourly via finger prick. 
Samples will cease to be collected when no parasites are seen in two subsequent, consecutive 
samples at the Malawi site; since the Zambia site does not possess skilled malaria microscopists, 
malaria smears will be obtained Q6 hourly through each participant’s 72 hours of enrollment but then 
read at a later time by a Malawian microscopist. For enrollment and clinical care considerations at the 


 
Aggressive Antipyretics for Fever 
 
 
Control in CNS Malaria 
 
 
Version 5.3 
21 Jan 2021 
Page 17 of 33 
Zambia site, malaria rapid diagnostic tests (RDTs) will also be performed to guide anti-malarial 
treatment decision-making. Values will be obtained by counting the proportion of 500 RBCs that are 
parasitized under high-power microscopic evaluation of a thin blood smear. The PCV will also be 
obtained at each time point and will be used to estimate RBC count using the formula PCV/8 = RBC X 
10^6 per microliter of blood. Estimated RBC count will be multiplied by the percent RBCs parasitized to 
arrive at the number of parasites per microliter of blood. 
 
 
12.2.4 Parasite hemozoin will be assessed as the percentage of parasites with hemozoin deposition 
based upon 100 parasites viewed in a high powered field at each qPC. 
 
12.2.5 Fever exposure as measures by the area under the curve (AUC) for 72 hours for fever ≥ 38.5ºC   
 
 
12.3 Additional demographic and clinical data to be collected 
 
 
 
12.3.1 Gender 
 
12.3.2 Age 
12.3.3 Seizure history 
12.3.4 Admission temperature 
12.3.5 Difficult birth history 
12.3.6 Developmental status as assessed by Ten Question screen 
12.3.7 Family history of seizures 
12.2.8 Retinopathy status in comatose subjects 
 


 
Aggressive Antipyretics for Fever 
 
 
Control in CNS Malaria 
 
 
Version 5.3 
21 Jan 2021 
Page 18 of 33 
13. Participant timeline 
 
 
Table 4.  
STUDY PERIOD 
 
Enrolme
nt 
 
Allocation 
(Day 0) 
Day 0 
(hrs 0-24) 
Day 1 
(hr 24-48) 
Day 2 
(hr 48-72) 
Discharge 
(d/c) 
Enrolment 
 
 
 
 
 
 
Initiation of anti-malarial therapy 
X 
 
 
 
 
 
Physical Exam 
X 
 
 
 
 
 
Medical/Treatment History 
X 
 
 
 
 
 
Eligibility Screen 
X 
 
 
 
 
 
Informed consent 
X 
 
 
 
 
 
Allocation 
 
X 
 
 
 
 
Interventions 
 
 
 
 
 
 
Aggressive antipyretics 
 
 
      Acetaminophen 
 
* If the child has received 
acetaminophen in the past 24 hours, no 
loading dose will be given. 
 
30 mg/kg* 
15 mg/kg Q6 hours (starting at 
enrollment (hour 00) and continuing 
through hour 72 including a final 
dose at hour 72) 
 
      Ibuprofen 
 
10 mg/kg 
10 mg/kg Q6 hours (starting at 
enrollment (hour 00) and continuing 
through hour 72 including a final 
dose at hour 72) 
 
 
 
 
Cooling fan if T≥38.5 persists for 
more than 1 vitals assessment (6 
hours) after aggressive antipyretics 
 
Standard of care 
 
 
      Acetaminophen 
 
15 mg/kg 
if T≥38.5C 
15 mg/kg Q6 hours if T≥38.5C 
(starting at enrollment (hour 00) and 
continuing through hour 72 including 
a final dose at hour 72) 
 
 
 
 
Cooling fan if T≥38.5 persists for 
more than 1 vitals assessment (6 
hours) after acetaminophen 
 
Safety monitoring 
 
 
 
 
 
 
Vomiting assessment 
Twice daily on rounds  
Nasogastric tube (NGT)  
injury assessment 
Twice daily on rounds while NGT in place 
Hypoglycemia 
Q6 hourly until BCS=5 or GCS=14 or with any suspected seizure 
Lactic acidosis > 24 hours  
 
 
x 
x 
x 
x 
Clinical evaluation for jaundice 
 
 
Twice daily on rounds 
Bilirubin & creatinine check 
 
x 
x 
x 
x 
x 
Screen for occult blood loss 
 
 
x 
x 
x 
x 


 
Aggressive Antipyretics for Fever 
 
 
Control in CNS Malaria 
 
 
Version 5.3 
21 Jan 2021 
Page 19 of 33 
 
14. Sample size 
The primary analysis in this study will involve a comparison of the adjusted mean Tmax between the 
treatment groups. In the BMPES study, the difference in mean Tmax for children with vs. without 
behavioral disorders was 0.5ºC, and it was 0.9ºC between those with and without epilepsy (2). A 
receiver operating characteristic curve analysis suggests that a good balance between sensitivity and 
specificity for Tmax in predicting epilepsy is achieved for a Tmax of 38.9ºC and the mean Tmax for 
children who experienced epilepsy was 39.4ºC suggesting that a reduction in temperature of 0.5ºC is a 
clinically meaningful reduction. CM at the proposed study sites has a mortality rate of ~15% and most 
children who die will do so within 12-24 hours after admission and are unlikely to benefit from fever 
reduction measures. The effect of mortality on the sample size is manifested through attenuation of the 
group difference in mean Tmax of 0.5 ºC. Under the assumption that mortality is comparable in the two 
groups and that there is no treatment effect in those who die, the attenuated treatment effect will be 
(0.5 × 0.85) + (0.0 × 0.15) = 0.425 ºC. Assuming a standard deviation of the maximum temperature of 
1.1 ºC as was present in the BMPES study population, a sample size of 142 children per group will 
provide 90% power to detect a group difference in mean Tmax of 0.425ºC, using a two-sample t-
test and a 5% significance level (two-tailed).  The 0.5ºC threshold (before attenuation) is based on 
our observational data that adverse neurologic outcomes in cerebral malaria occur at mean Tmax 
differences of 0.5ºC (2). 
 
For the outcome of acute symptomatic seizures, data collected during past malaria studies (2, 19) 
suggest that the incidence of seizures after admission will be 40% in children with CM and 24% in CNS 
malaria. Assuming an overall seizure incidence after enrollment of 32% in the usual care group 
(68% with no seizures, 25% with a single brief seizure, and 7% with multiple or prolonged 
seizures), a sample size of 142 children per group will provide 80% power to detect a shift in the 
aggressive antipyretic treatment group to 82% with no seizures, 15% with a single brief seizure, 
and 5% with multiple or prolonged seizures, representing a common log-odds ratio of 0.7656. 
The method due to Whitehead(76) was used for this calculation. 
 
Since we are preferentially recruiting to ensure that approximately 50% of children enrolled have CM 
and past experience indicates that 70% of CM admissions during the rainy season (i.e., malaria 
season) are retinopathy positive, we anticipate that there will be 100 children included in the secondary 
analysis of Tmax differences between treatment groups among children with CM and CNS parasite 
sequestration compared to all others. Assuming a standard deviation of Tmax of 1.1 ºC(2), a sample 
size of 50 children per group will provide 80% power to detect a group difference in mean Tmax 
of 0.62ºC (after attenuation due to mortality), using a two-sample t-test and a 5% significance 
level (two-tailed). Sample size considerations cannot be provided for Hypothesis 2 due to the absence 
Structured screening evaluation 
for clotting or bleeding disorder 
 
 
Twice daily on rounds 
Assessments 
 
 
 
 
 
 
Vital signs (including temperature) 
 
X 
Q6 hours 
 
Continuous temperature monitor 
 
X 
X 
X 
X 
 
EEG 
 
 
Daily for BCS≤4, GCS≤10, suspect 
seizure 
 
Thick and thin smear 
 
X 
Q6 hours until two consecutive 
negative smears (until the 72-hr. 
point at the Zambia site) 
 
qPC 
 
X 
Q6 hours until two consecutive 
negative smears at the Malawi site 
(until the 72-hr. point at the Zambia 
site) 
 
HRP2 
X 
X 
Q6 hours 
 
Neurologic evaluation 
X 
 
 
 
 
X 


 
Aggressive Antipyretics for Fever 
 
 
Control in CNS Malaria 
 
 
Version 5.3 
21 Jan 2021 
Page 20 of 33 
of preliminary data on HRP2 levels, including the absence of any reasonable data on standard 
deviation for HRP2 levels or the percentage of mature parasites. 
15. Recruitment 
15.1 Blantyre.  
 
Recruitment will be directly from the Accident and Emergency Department where study nurses 
knowledgeable of the inclusion criteria will be based. Patients will be directly transferred to the Pediatric 
Research Ward (PRW). The PRW serves as the de facto intensive care unit for the hospital, hence 
many of the eligible patients will be transferred to the PRW independent of this trial  
 
15.2 Lusaka.  
 
 
Recruitment will be directly from the Emergency Department where a study nurse knowledgeable of the 
inclusion criteria will be based. Patients will be transferred to the Pediatric Intensive Care Unit (PICU) or 
the Admission Ward beds adjacent to the PICU depending upon medical need.   
 
15.3 Chipata.  
 
Recruitment will be directly from the Emergency Department where study staff knowledgeable of the 
inclusion criteria will be based. Patients will be transferred to the High Acuity section within the Pediatric 
Ward.   
 
16.0 Methods: Randomization and Assignment of Interventions 
 
16.1 Randomization 
Eligible children whose parent or guardian has provided written informed consent will receive treatment 
allocation as determined by randomization provided in sealed opaque envelopes maintained by the 
study pharmacist in the unlikely event that unblinding is needed. Patients will be assigned to treatment 
groups with 1:1 allocation using blocked randomization.  Randomization will be stratified by country and 
blocked randomization will be used due to the potential small sample size in Zambia. UR-Biostatistics 
will be responsible for generating the randomized list of subject assignments and providing sequentially 
numbered sealed opaque envelopes. Tmax and seizure outcomes will be determined in the 72 hours 
following enrollment. Safety assessments will occur during the 72-hour inpatient observation period. A 
30-day follow-up is standard of care for CM survivors at both study sites. Any child discharged with 
unresolved laboratory or clinical concerns will have a 30-day follow-up visit scheduled. 
 
Table 5: Overview of Treatment after Randomization 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* If 
the child has received acetaminophen in the past 24 hours, no loading dose will be given.  
Aggressive Antipyretics 
Usual Care (WHO 2015 Guidelines) 
Initial Treatment 
30mg/kg acetaminophen* + 10mg/kg ibuprofen 
 
If temp ≥ 38.5, add acetaminophen placebo 
 
acetaminophen and ibuprofen placebos 
 
 If temp ≥ 38.5, add acetaminophen 
15mg/kg Q6 
Subsequent Management based upon Q6 hourly temperatures 
Continue acetaminophen 15mg/kg and ibuprofen 
10mg/kg Q6 hourly for 72 hours (from hr-00 through 
hr-72 including a final dose at hour 72) 
 
If temp ≥ 38.5, give acetaminophen placebo Q6 
hourly 
Continue acetaminophen and ibuprofen 
placebos Q6 hourly for 72 hours (from 
hr-00 through hr-72 including a final dose 
at hour 72) 
 
If temp ≥ 38.5, add acetaminophen 
15mg/kg Q6  
Management if continued temperature ≥ 38.5 
Cooling fan 
Cooling fan 


 
Aggressive Antipyretics for Fever 
 
 
Control in CNS Malaria 
 
 
Version 5.3 
21 Jan 2021 
Page 21 of 33 
16.2 Allocation 
 
 
16.2 (a) Sequence generation.  
 
The randomization process is designed to be blinded to data collectors. The randomization plan will be 
developed by the unmasked programmer at UR Biostatistics. It will be generated using a SAS program 
in accordance with Biostatistics standard operating procedures. Subjects will be randomly assigned 
with equal allocation to the two treatment groups. The randomization will be stratified by country, and 
will include blocking to ensure approximately equal allocation of the treatments within each stratum 
after a specified number of subjects have been enrolled in that stratum. The randomized allocation will 
be provided to the compounding and study site pharmacists preparing the intervention and placebos. 
Sealed envelopes indicating allocation will be provided at the study sites if unblinding is needed for 
patient care. 
16.2 (b) Allocation concealment mechanism.  
 
Patients will be assigned to treatment groups using blocked randomization with randomly selected 
block sizes. Randomization will delineate treatment allocation to sequential, previously delineated study 
IDs for each site. Details of random allocation will be provided to the local study pharmacist for 
preparation of treatment packages by the US-based compounding pharmacist as received from the 
unmasked UR Biostatistics programmer. In addition sealed opaque envelopes with treatment allocation 
by study ID will be provided to the study sites in case there is the need to break the code for an 
individual patient. At the completion of the study, all envelopes will be returned to UR Biostatistics.  
 
17. Blinding 
 
Allocation will be concealed from all staff. Continuous temperature readings will be captured 
electronically but the display will be concealed from nursing staff who provide treatment for interim 
fevers based upon treatment protocol and temperature measured clinically per usual care on the ward. 
The EEG interpreter will be blinded to allocation and temperature.  
 
Methods: Data collection, management, and analysis 
 
18. Data collection methods 
 
18.1 Collection of data 
 
18.1.1 Temperature and Tmax 
a. Temperature. Temperature for clinical care purposes will be acquired from the vital sign 
assessments performed by the study nurses.  
b. Tmax for primary study outcome will be acquired from the continuous temperature monitoring 
device. This data will not be visible to or made available to study nurses providing clinical care 
 
18.1.2 Fever Exposure. Fever exposure is the area under the curve (AUC) for 72 hours for fever ≥ 
38.5ºC and this will be uploaded into the REDCap database from the CRF. The raw data captured 
every 2 minutes will also be captured in an Excel spreadsheet to then be emailed to the biostatistician 
separately. 
 
18.1.3 Seizure activity. Seizure activity will be recorded by the study clinicians on a fitting chart 
attached to each subject file. This will capture the time, nature, and treatment of each episode of 
seizure activity. Subjects will also undergo a routine 30-minute 12-lead EEG every day while BCS≤ 4 or 
GCS≤10. Seizure activity on EEG adhere to ILAE guidelines for electrographic seizure 


 
Aggressive Antipyretics for Fever 
 
 
Control in CNS Malaria 
 
 
Version 5.3 
21 Jan 2021 
Page 22 of 33 
 
18.1.4 qPC. qPC will be determined by standard protocol as delineated in the SOP. Briefly the number 
of parasites in 500 RBCs will be determined by microscopy. This will be translated to parasites per 
microliter using the PCV divided by eight as an estimate of RBC X 10^6 per microliter (ul). 
 
18.1.5 HRP2. HRP2 concentration per ul will be determined by previously published methods (51). 
Briefly, plasma will be obtained from the microhematocrit tubes used for PCV determination. After 
determination of PCV (if clinically needed), tubes will be scored at the RBC/plasma interface with a 
triangular file and broken. A narrow pipette tip will be inserted in the plasma containing portion and the 
plasma removed. Plasma will be transferred to a bar code-labeled microcentrifuge tube and stored at -
20°C until analysis.  
 
At the time of analysis, plasma diluted at a ratio of 1:500 in phosphate buffered saline (PBS) as well as 
a titration of a stock of recombinant HRP2, will be plated onto a plate precoated with anti-HRP2 
antibody (Cellabs, Brookvale, Australia). The manufacturer’s protocol will then be followed, except for 
the modification of all incubations being carried out at 37°C in a humidified chamber. In brief, a 1-hour 
sample incubation step will be followed with extensive washing with PBS/0.1% Tween. One hundred 
microliters of the second conjugated antibody will be plated and allowed to incubate for 1 hour. The 
conjugate will subsequently be washed off and 100 μL of substrate added for 15 minutes, during which 
color change will be observed. This reaction will be stopped with 1N HCl and the plate analyzed at 
optical density (OD) 450. A standard curve will be generated from the recombinant protein and the 
readings from the diluted unknown samples will be compared to this curve to calculate HRP2 levels. If 
the initial dilution of the sample results in an OD reading that does not lie within the linear range of the 
recombinant protein, the sample will be rediluted at either 1:1000 or 1:100 to result in OD values within 
the dynamic range of the ELISA. Samples that remained off scale low, despite redilution, will be 
assigned a value equivalent to the lowest possible detection value of the ELISA. 
 
18.1.6 EEG.  
 
EEGs will be obtained on the day of admission and daily thereafter until recovery (i.e., if BCS≤4, 
GCS≤10). EEGs will be obtained using a modified 10-20 system, and meet the American 
Electroencephalography Society’s guidelines for EEG (77).  For clinical purposes EEGs will be 
systematically reviewed by the neurophysiologist providing clinical support for the respective site the 
day the EEG is obtained. 
 
18.1.7 Data collection Process  
Data will be collected on paper-based forms included in the subjects’ clinical files during the admission, 
and study-specific variables will be captured in these forms by study personnel. A paper-based data 
abstraction to a case-report form will then be completed by local study personnel before double data 
entry into REDCap. 
 
18.2 Retention of subjects 
 
 
 
The study period is limited to 72 hours and >90% of children admitted with CNS malaria are inpatient 
for 72 hours or longer. To encourage retention among those ready for discharge before the study 
completion, transportation home and a meal allowance will be provided for their parent(s). The informed 
consent process will also be very explicit and clear about the need for at least a 72-hour admission and 
children with parents unwilling to commit to this will not be enrolled. If clinical or safety concerns are 
present at discharge, a 30-day follow-up will be scheduled as per clinical care protocol for both study 
sites. 
19. Data management 
 
 
The REDCap system is a secure, web-based application that is flexible enough to be used for a variety 
of types of research. It provides an intuitive interface for users to enter data and real-time validation 
rules (with automated data type and range checks) at the time of data entry. REDCap offers easy data 
manipulation with audit trails and functionality for reporting, monitoring and querying patient records, as 


 
Aggressive Antipyretics for Fever 
 
 
Control in CNS Malaria 
 
 
Version 5.3 
21 Jan 2021 
Page 23 of 33 
well as an automated export mechanism to common statistical packages (SPSS, SAS, Stata, R/S-
Plus). The Double Data entry feature allows a project administrator to designate two users per study to 
perform double data entry. Other users are then able to compare the data entry results, using the data 
comparison tool. This requires that the Double Data Entry feature be activated for the study. 
 
Through the University of Rochester Medical Center’s Center for Health and Technology (CHeT), the 
Clinical Translational Science Institute (CTSI) Informatics Core will serve as a central facilitator for data 
processing and management. REDCap data collection projects rely on a thorough, study-specific data 
dictionary defined in an iterative self-documenting process by all members of the research team, with 
planning assistance from the CTSI Informatics Core. CHeT’s iterative development and testing 
processes results in a well-planned data collection strategy for individual studies. REDCap servers are 
housed in a local data center at the University of Rochester and all web-based information transmission 
is encrypted. REDCap was developed in a manner consistent with HIPAA security requirements and is 
recommended to University of Rochester researchers by the URMC Research Privacy Officer and 
Office for Human Subject Protection. Access to data in the REDCap application and database will be 
controlled by using user definitions and permissions. The PI will have access to all study data and will 
direct access for all users.  Audit logs are created automatically within the REDCap application to 
capture the complete user history of database activity.  
 
Data entry for the subject is expected to be complete within one week of randomization. Most data 
entry errors will be resolved by the Double Data Entry process operating on local machines at each 
site. Therefore, Data Management will be primarily responsible for ensuring CRFs are entered in a 
timely manner and are complete. Reports of delayed data entry and missing CRF elements will be 
generated weekly for the CHeT project manager to review with sites.  
 
20. Statistical methods 
 
The analyses presented below will be performed according to the intention-to-treat principle and will 
include all available data from all randomized subjects. The assumptions underlying all statistical 
models will be thoroughly checked using graphical and inferential methods and remedial measures will 
be taken (e.g., transformations, consideration of alternative models) if these assumptions are found to 
be seriously violated. A significance level of 5% will be used for hypothesis testing. 
 
Analytic Plan for Hypothesis 1 (i):  
Children who receive aggressive antipyretic therapy will have lower mean Tmax during the 72-hour 
treatment period based upon continual temperature assessments. 
The analysis of the Tmax will involve fitting an analysis of covariance model with treatment group as the 
factor of interest, site and disease severity (CM vs CNS malaria) as stratification factors, and admission 
temperature as a covariate. The estimated treatment effect (difference in adjusted group means 
between the aggressive antipyretic therapy and usual care groups) and its associated 95% confidence 
interval, as well as a t-test for significance of the treatment effect, will be derived from this model. 
 
For subjects who do not complete the 72-hour follow-up period, the maximum temperature observed 
during their abbreviated follow-up will be used for the primary analysis. A secondary analysis will be 
performed that is the same as the primary analysis except that the contribution of each subject’s data to 
the analysis will be weighted by the time that they are followed (percentage of the 72-hour follow-up 
period).  
 
To evaluate the effects in the study population most analogous to the BMPES population, a secondary 
analysis will include terms added to the above analysis of covariance model representing the main 
effect of subgroup (CM with CNS parasite sequestration vs. all others) and the interaction between 
treatment and subgroup. For purposes of this analysis, CM will be defined as having a BCS ≤2 or GCS 
≤10 and CNS parasite sequestration will be defined as having an initial HRP2 ≥1700 ng/dl. This model 
will permit estimation of the treatment effects within each subgroup (with associated 95% confidence 
intervals and p-values) and a test for significance of the treatment effects between the subgroups. 
Exploratory analyses will be performed using the above methods for the log-transformed fever 
exposure outcomes. For subjects who do not complete the 72-hour follow-up period, the AUC falling 


 
Aggressive Antipyretics for Fever 
 
 
Control in CNS Malaria 
 
 
Version 5.3 
21 Jan 2021 
Page 24 of 33 
above the fever cut-off during the subject’s abbreviated follow-up will be multiplied by the inverse of the 
percentage of time that the subject was followed for the primary analysis. Secondary analyses of these 
outcomes will be performed weighting each subject’s contribution by the time that they are followed, as 
described above for Tmax. 
 
Analytic Plan for Hypothesis 1(ii):  
Children who receive aggressive antipyretic therapy will be less affected by acute symptomatic seizures 
during the malaria infection based upon clinical assessments and daily routine EEGs for those with 
BCS≤4 and GCS≤10 
 
To compare seizure outcome between the treatment groups, outcome will be defined as a three-level 
ordinal variable: no seizures, a single brief (<15 minute) seizure, and multiple or prolonged (>15 
minutes) seizures. The analysis of this outcome variable will involve fitting an ordinal logistic regression 
model (proportional odds model)(78) with treatment group as the factor of interest, site and disease 
severity as stratification factors, and history of prior seizures and pre-existing developmental delay as 
covariates. The estimated treatment group odds ratio, along with its associated 95% confidence interval 
and p-value, will be derived from this model. If the proportional odds assumption appears to be 
seriously violated, a multinomial logistic regression model will be used instead (78).  
 
Analytic Plan for Hypothesis 2: 
We hypothesize that fever treatment will reduce sequestration resulting in lower HRP2 levels based 
upon area under the curve during the 72-hour treatment period and an associated transient paradoxical 
increase in peripheral parasitemia with a higher proportion of older parasites seen. 
AUC has been selected as the outcome due to substantial between-subject heterogeneity of the level-
time curves and because subjects will be at different time points in their illness in terms of treatment 
(some having received antimalarials as an outpatient prior to admission). As such, if a more rapid 
reduction in HRP2 occurs in general, it should be captured by this AUC. The analyses of the area under 
the HRP2 level-time curve (log-transformed) will involve fitting an analysis of covariance model with 
treatment group as the factor of interest, site and disease severity as stratification factors, and time 
since the initiation of antimalarial treatment and log-transformed HRP2 level at t=0 as covariates. The 
estimated treatment effect (difference in adjusted group means between the aggressive antipyretic 
therapy and usual care groups) and its associated 95% confidence interval, as well as a t-test for 
significance of the treatment effect, will be derived from this model. For subjects who do not complete 
the 72-hour follow-up period, the area under the HRP2 level-time curve (log-transformed) observed 
during the subject’s abbreviated follow-up will be multiplied by the inverse of the percentage of time that 
the subject was followed for the primary analysis. A secondary analysis of this outcome will be 
performed weighting each subject’s contribution by the time that they contribute HRP2 data. 
 
We expect aggressive fever reduction to facilitate release of mature sequestered parasites (evident by 
the hemozoin they contain) from the CNS. In an exploratory analysis, the mean percentage of mature 
parasites across all positive blood smears for each child taken Q6 hourly will be compared in the ‘usual 
care’ vs. ‘aggressive antipyretic treatment’ groups using a t-test. In ‘usual care’, less than 5% of 
parasites typically have evidence of hemozoin deposition but the natural history of parasite hemozoin 
clearance is unknown.  
 
Interim Analyses  
Interim analyses for efficacy will be performed at the end of the second and third recruiting malaria 
seasons. An upper boundary will be determined using the O’Brien-Fleming α-spending function to 
control the overall probability of a Type I error at 2.5% (since only an upper boundary will be considered 
for early stopping).  
Methods: Monitoring 
21. Data monitoring 
 
 
This study will be overseen by Local Study Monitors (LSM) at each study site and a Data and Safety 
Monitoring Board (DSMB). The LSMs will review adverse events and outcomes weekly. For Serious 
Adverse Events (SAEs, defined below) and any AEs of grade 3 or higher, the PI will be alerted 


 
Aggressive Antipyretics for Fever 
 
 
Control in CNS Malaria 
 
 
Version 5.3 
21 Jan 2021 
Page 25 of 33 
immediately and the LSMs will provide expedited 48-hour review which will be circulated to the DSMB 
and PI on completion. LSMs are individuals with substantial experience caring for children with severe 
malaria. Plans for detailed management for adverse events are outlined in Table 3. Weekly LSM 
reports will be provided to the DSMB at ~6 monthly intervals including those provided for the annual 
meeting and interim analysis. If the LSM develops concerns regarding the safe continuation of the 
study, he/she will inform the PI to suspend further study enrollment pending DSMB review and 
discussion. If the DSMB identifies a concern that may require halting of enrollment or modification of 
the protocol, they will contact the PI and have a meeting or teleconference with other members of the 
study team. NINDS will be involved as appropriate, in order to come to a final decision regarding course 
of action. 
 
SAEs include 
1. Death 
2. Neurologic sequelae evident at discharge 
3. Aspiration requiring discontinuation of the study drug 
4. The development of clinically evident bleeding or platelet dysfunction (not occult blood in urine or 
stool) 
5. Renal injury requiring management other than simple discontinuation of the intervention 
6. The development of clinically evident jaundice or an increase in bilirubin of > 5 mg/dL from baseline  
7. Prolonged hospitalization potentially related to the study intervention 
 
If study enrollment is suspended for safety reasons, the PI will notify the NIH, the supervising IRBs (the 
University of Rochester’s Research Subjects Review Board, The University of Malawi’s College of 
Medicine Research Ethics Committee, the University of Zambia’s Biomedical Research Ethics 
Committee) and the appropriate regulatory authorities including Malawi’s Pharmacy, Medicines and 
Poisons Board and Zambia’s Medicines Regulatory Authority.  
 
Enrollment occurs from January-June during the malaria seasons of years 1-4 of this award, except for 
the Chipata site which will enroll throughout each year given the high malaria admission rates at this 
setting year round. The DSMB consists of four clinician scientists with expertise in severe malaria in 
children who have worked in other African countries, plus a US-based biostatistician who has held this 
role on numerous DSMBs for other clinical trials. SAEs are reported to the DSMB within 48 hours, all 
other AEs reported to the DSMB Q 6-monthly and an interim safety analysis will be completed annually. 
As noted in Section 20 above, interim analyses for efficacy will also be conducted at the completion of 
Years 2 and 3 using an upper boundary determined by an O’Brien-Fleming α-spending function to 
control the overall probability of a Type I error at 2.5% (since only an upper boundary will be considered 
for early stopping). Interim analyses will also be performed for excess mortality in the aggressive 
antipyretic treatment group at the end of each of the first three recruiting malaria seasons. A lower 
boundary will again be determined using an O’Brien-Fleming α-spending function to control the overall 
probability of a Type I error. The DSMB will also carefully consider other adverse events in terms of 
treatment group imbalances, with particular attention paid to vomiting, recurrent hypoglycemia, elevated 
creatinine or bilirubin, blood transfusion requirements, identification of occult blood, and clinically 
evident thrombocytopenia or bleeding. Continuous variables that will be monitored include hours with 
lactic acidosis, maximum lactate, bilirubin, and creatinine levels, and parasite clearance time. Fisher’s 
exact tests (or chi-square tests) will be used to compare the treatment groups with respect to 
dichotomous outcomes, and t-tests (or Wilcoxon rank sum tests) will be used to compare the treatment 
groups with respect to continuous outcomes. A log-rank test will be used to compare the treatment 
groups with respect to parasite clearance time. If potential safety concerns are identified, the DSMB 
may consider recommending modification (or halting) of the trial. The DSMB will provide an annual 
review of the interim analysis through a combination of virtual and face-to-face meetings and provide a 
written summary report within 1 week of the annual review meeting.  
 
An initial meeting between the study leadership and the DSMB will take place prior to enrollment of the 
first study subject, to review study procedures and come to agreement on the DSMB Charter. The 
Charter will document the role and function of the DSMB including the frequency and format of DSMB 
meetings, the format of reports to be prepared for DSMB review, guidelines for interim analyses for 
safety and efficacy, extent of blinding of the DSMB, and rules for communication among the study 
leadership and the DSMB. 


 
Aggressive Antipyretics for Fever 
 
 
Control in CNS Malaria 
 
 
Version 5.3 
21 Jan 2021 
Page 26 of 33 
 
The Department of Biostatistics and Computational Biology (DBCB) at the University of Rochester will 
prepare formal reports for each interim analysis for the DSMB. These reports will include appropriate 
introductory material (study synopsis, current status of the trial, etc.), information on recruitment and 
retention, subject characteristics, subject disposition, treatment discontinuations, adverse events 
(including serious adverse events), laboratory test results, and other safety data. This information will 
be provided by treatment group, where applicable. 
 
Approximately one month before a scheduled DSMB meeting, the database will be transferred from 
CHeT to the DBCB using a long-established protocol, and a numbered version of the analytic database 
will be created by the DBCB.  All DSMB reports will refer to the specific version number of the database 
that is used in their preparation, as well as the date on which the database was created. The 
designated DBCB programmer who generated the randomization plan for the trial will prepare the 
DSMB reports. The treatment groups in the report will be coded as “A” and “B”, which can be linked to 
the identities of the actual treatment groups if requested by the DSMB. 
 
 
22. Harms 
 
CM is associated with high rates of morbidity and mortality. The expected outcomes related to the 
disease itself include severe anemia requiring blood transfusions, hyperlactatemia, acidosis, prolonged 
coma, hypoglycemia, severe thrombocytopenia, hyponatremia, extreme hyperpyrexia, seizures, and, 
neurologic sequelae including blindness, hemiparesis, hypotonia, and mutism. Death is also a common 
outcome, occurring in 16% of pediatric CM patients on the QECH Research Ward over the past 5 
years. All study subjects will receive treatment and management for these conditions consistent with 
the WHO’s guidelines for the management of severe malaria. 
 
Known potential harms from the Intervention are listed below 
 
22.1 Aspiration: Study subjects will be closely monitored clinically for signs of aspiration including Q4-
hourly assessments of oxygen saturation. The Q4-hourly assessments are intended to be done only if 
coma score is sub-normal, otherwise this metric need be done only per hospital ward protocol. If 
oxygen saturations are below 95%, the ward attending will be notified to make a physician-level 
assessment (auscultation, urgent PCV, etc.) and determine if aspiration is the potential underlying 
cause. If oxygen saturation declines and remains lower than the pre-aspiration baseline, the NGT will 
be placed to suction to remove any remaining gastric contents, the intervention will be discontinued and 
the NGT removed. Otherwise, the decision to discontinue the study drug intervention is at the discretion 
of the attending physician.  
 
22.2 Complications of NGT placement and maintenance: If placement/maintenance of the NGT by 
experienced staff is difficult and results in nasal trauma and/or significant epistaxis and the study 
subject is comatose and/or unable to swallow, the intervention will be discontinued and the NGT 
removed. Necessary measures to ameliorate any bleeding will be taken. 
 
22.3 Vomiting: Although common in the early stages of malaria, once comatose study participants with 
CM do not usually vomit. If vomiting occurs in a comatose study participant, the NGT will be placed to 
suction to remove the remaining gastric contents, oxygen saturations will be assessed, and once 
gastric contents have been removed the NGT will be removed and the intervention will be discontinued. 
 
22.4 Acidosis: Lactic acidosis is common on admission but generally resolves within 24 hours. 
 
22.5: Hyperbilirubinemia: Liver dysfunction is common in CNS malaria. Children with a bilirubin on 
admission of above 3 or those with frank jaundice are excluded. The study intervention will be halted if 
after enrollment the bilirubin escalates >5mg/dL or the child develops clinical jaundice. 
 
22.6 Renal insufficiency: If the creatinine increased by >0.5 mg/dL from baseline or a doubling of the 
baseline creatinine, the study intervention will be stopped.  
 


 
Aggressive Antipyretics for Fever 
 
 
Control in CNS Malaria 
 
 
Version 5.3 
21 Jan 2021 
Page 27 of 33 
22.7 Increased risk of bleeding: Thrombocytopenia is common during malaria infections. The use of 
ibuprofen may decrease platelet function and could therefore increase the risk of abnormal bleeding. 
Children with any history of thrombocytopenia prior to the acute malaria illness will be excluded. 
Structured clinical screening will also be conducted to assure anyone with evidence of abnormal 
bleeding is excluded from enrollment. During the study, children will be evaluated twice daily by an 
experienced clinician who will repeat the structured assessments to identify any clinical evidence of 
abnormal bleeding/poor clotting and the intervention will be halted in any child that develops 
signs/symptoms. 
23. Auditing 
 
Prior to the initiation of the study, harmonization training sessions will be conducted for clinician co-
investigators, the investigators and their study coordinators for each site.  This meeting will include a 
detailed discussion of the protocol, performance of study procedures, CRF completion, simulation of 
study procedures and specimen collection methods, as applicable.  Subsequent detailed local training 
sessions with ward nurses and clinicians will be held at each site. 
 
Prior to commencing enrolment, the University of Malawi Research Support Centre (RSC) will conduct 
an external audit of the study in Malawi and a certified RSC auditor will conduct a similar audit of the 
Zambian site to assure the clinical trial is in compliance with Good Clinical Practices. 
 
After completion of the data entry process, computer logic checks will be run to check for such items as 
inconsistent study dates and outlying laboratory values.  Any necessary correction will be made to the 
database and documented via addenda or audit trail.  A manual review of selected line listings will also 
be performed at the end of the study.    
 
The Project Coordinator will assist the PI in assuring protocol compliance, ethical standards, regulatory 
compliance and data quality at the clinical sites. The coordinator will provide real time daily review of all 
study files to assure protocol compliance and documentation completeness. The study sites may also 
be subject to quality assurance audits by the NINDS or its designees and appropriate regulatory 
agencies. Audits may include reviews of paper or electronic records. 
 
Ethics and dissemination 
24. Research ethics approval 
 
In addition to the oversight provided at each site by the local study monitors, the study has been 
approved by the following Institutional Review Boards: 
 
The University of Zambia’s Biomedical Research Ethics Committee FWA00000338 (UNZA BREC) 
The University of Malawi’s College of Medicine Research Ethics Committee FWA00011868 (COMREC) 
The University of Rochester’s Research Subjects Review Board FWA00009386 (RSRB) 
 
An intra-institutional agreement was generated between the University of Rochester’s RSRB and 
Michigan State University’s (MSU) Biomedical Institutional Review Board FWA00004556 (BIRB). 
Michigan State University’s BIRB and Boston Children’s Hospital (BCH) IRB have agreed to rely on 
University of Rochester’s RSRB.  
 
While in Malawi, the MSU PI is responsible for overseeing subject recruitment and data collection at 
Queen Elizabeth Central Hospital. As part of data cleaning process, he will also have access to data 
with patient identifiers.  
 
While in Zambia, the BCH PI will serve as a clinician. Her responsibilities also include data collection 
and conducting EEG’s on study patients.  As part of data cleaning, she will also have access to data 
with patient identifiers. 
 


 
Aggressive Antipyretics for Fever 
 
 
Control in CNS Malaria 
 
 
Version 5.3 
21 Jan 2021 
Page 28 of 33 
Our office takes responsibility for the required IRB reports (the University of Rochester’s Research 
Subjects Review Board, The University of Malawi’s College of Medicine Research Ethics Committee, 
and the University of Zambia’s Biomedical Research Ethics Committee) within Malawi and Zambia. 
Regular communications between the MSU PI and BCH PI, Local Safety Monitoring (LSM) and the 
Lead PI ensure that data collected and contact information is up-to-date. 
 
No human subjects contact will occur at any of the US-based sites. All data exported to the US is de-
identified prior to transfer. All RSRB determinations regarding this work will be shared with the non-
affiliated researchers in a timely fashion.  
 
All laboratory specimens, evaluation forms, reports, and other records that leave the participants 
enrollment sites will be identified only by the study ID number to maintain subject confidentiality. All 
paper records will be kept in a secure study offices, within locked file cabinet. All computer entry and 
networking programs will be done using IDs only. Clinical information will not be released without 
written permission of the subject or the subject’s parent or guardian, except as necessary for monitoring 
by the supervising IRBs (the University of Rochester’s Research Subjects Review Board, The 
University of Malawi’s College of Medicine Research Ethics Committee, the University of Zambia’s 
Biomedical Research Ethics Committee) and regulatory agencies, (Medicines and Poisons Board in 
Malawi and Zambia Medicines Regulatory Authority), the sponsor, and/or the sponsor’s designee.  Any 
presentation, abstract, or manuscript will be made available to the sponsor and IRBs as part of routine 
annual reports. 
 
25. Protocol amendments 
 
 
The protocol included in this submission, which was developed in accordance with the 2013 SPIRIT 
Guidelines, and any subsequent modifications will be reviewed and approved by the ethical review 
boards listed in Section 24, the local study monitors, and an Advisory Committee which will include 
leadership from the Department of Pediatrics in both African institutions. Any modifications to the 
protocol which may impact on the conduct of the study, potential benefit of the patient or may affect 
patient safety, including changes of study objectives, study design, patient population, sample sizes, 
study procedures, or significant administrative aspects will require a formal amendment to the protocol. 
Such an amendment will be agreed upon by the University of Rochester, NINDS, and the Advisory 
Committee, and approved by the IRB prior to implementation, and notified to the health authorities in 
accordance with local regulations. Administrative changes of the protocol are minor corrections and/or 
clarifications that have no effect on the way the study is to be conducted. These administrative changes 
will be agreed upon by the Advisory Committee and will be documented in a memorandum. The IRB 
may be notified of administrative changes at the discretion of The PI. 
26. Consent  
 
 
Written informed consent from the parent/guardian will be required for enrollment. The discussion 
regarding consent as well as the consent form itself will be provided in the preferred language of the 
parent/guardian. A signed consent form will be obtained from the parent/guardian of each subject. The 
consent form will describe the purpose of the study, the procedures to be followed, and the risks and 
benefits of participation. Alternatives to enrollment and the right to withdraw participation at any time will 
also be explicitly included within the consent form. A copy of the consent form will be given to the 
guardian, and this fact will be documented in the subject’s record. Since these are all children under 12 
years with active CNS malaria at the time of the enrollment, no assent will be sought. 
27. Confidentiality 
 
All laboratory specimens, evaluation forms, reports, EEGs, and other records that leave the site will be 
identified only by the study ID number to maintain subject confidentiality.  All records will be kept in 
locked study-dedicated offices.  All computer entry and networking programs will be done using SIDs 
only.  Clinical information will not be released without written permission of the subject, except as 
necessary for monitoring by the involved institutions ethics review boards (RSRB, COMREC, and 


 
Aggressive Antipyretics for Fever 
 
 
Control in CNS Malaria 
 
 
Version 5.3 
21 Jan 2021 
Page 29 of 33 
UNZA BREC), the Malawi Pharmacy Medicines and Poisons Board, the Zambia Medicines Regulatory 
Authority, the NINDS, the OHRP, the sponsor, or the sponsor’s designee. 
 
28. Declaration of interests 
 
 
None of the investigators on the trial declare any competing interests. 
 
 
29. Access to data 
 
The DBCB will oversee the intra-study data sharing process, with input from the Principal Investigator. 
 
All Investigators (both US and host country) will be given access to the cleaned data sets. Individual 
country investigators will have direct access to their own site’s data sets, and will have access to other 
site’s data by request. To ensure confidentiality, data dispersed to project team members will be 
blinded of any identifying participant information. 
 
30. Ancillary and post-trial care 
 
Patients that are enrolled into the study are covered by indemnity for negligent harm through an 
indemnity arrangement arranged at each study site. Insurance to cover for non-negligent harm 
associated with the protocol will be procured prior to enrollment. This will include cover for additional 
health care, compensation or damages whether awarded voluntarily by the Sponsor, or by claims 
pursued through the courts.  
 
31. Dissemination policy 
 
31(a) Plans for dissemination 
 
 
The primary outcome of this study will be submitted for publication no later than one year after study 
completion. This manuscript, as well as any other manuscripts, posters, or abstracts, must be approved 
by the publication committee for approval prior to submission. Financial support from the NINDS will be 
acknowledged in all publications.   
 
 
31(b) Authorship eligibility guidelines 
 
The guidelines defined by the International Committee of Medical Journal Editors will be used in 
determining authorship on all papers, abstracts, and posters emanating from this study.  
 
31(c) Public access of data 
 
No later than three years from the close of the study we will deliver a completely de-identified data set 
to an appropriate data archive for sharing purposes.  
 
32. Informed consent material 
The final English version will be translated into the appropriate local languages. 
 
 
 
 
 


 
Aggressive Antipyretics for Fever 
 
 
Control in CNS Malaria 
 
 
Version 5.3 
21 Jan 2021 
Page 30 of 33 
References 
 
1. 
WHO. World Malaria Report 2013. Geneva: World Health Organization, 2013. 
2. 
Birbeck GL, Molyneux ME, Kaplan PW, Seydel KB, Chimalizeni YF, Kawaza K, et al. Blantyre Malaria 
Project Epilepsy Study (BMPES) of neurological outcomes in retinopathy-positive paediatric cerebral malaria 
survivors: a prospective cohort study. Lancet Neurol. 2010;9(12):1173-81. 
3. 
Carter JA, Lees JA, Gona JK, Murira G, Rimba K, Neville BG, et al. Severe falciparum malaria and 
acquired childhood language disorder. Dev Med Child Neurol. 2006;48(1):51-7. 
4. 
Carter JA, Mung'ala-Odera V, Neville BG, Murira G, Mturi N, Musumba C, et al. Persistent 
neurocognitive impairments associated with severe falciparum malaria in Kenyan children. J Neurol Neurosurg 
Psychiatry. 2005;76(4):476-81. 
5. 
Carter JA, Neville BG, White S, Ross AJ, Otieno G, Mturi N, et al. Increased prevalence of epilepsy 
associated with severe falciparum malaria in children. Epilepsia. 2004;45(8):978-81. 
6. 
Dondorp AM, Fanello CI, Hendriksen IC, Gomes E, Seni A, Chhaganlal KD, et al. Artesunate versus 
quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, 
randomised trial. Lancet. 2011;376(9753):1647-57. 
7. 
Carme B, Bouquety JC, Plassart H. Mortality and sequelae due to cerebral malaria in African children in 
Brazzaville, Congo. Am J Trop Med Hyg. 1993;48(2):216-21. 
8. 
Bondi FS. The incidence and outcome of neurological abnormalities in childhood cerebral malaria: a 
long-term follow-up of 62 survivors. Trans R Soc Trop Med Hyg. 1992;86(1):17-9. 
9. 
Meremikwu MM, Asindi AA, Ezedinachi E. The pattern of neurological sequelae of childhood cerebral 
malaria among survivors in Calabar, Nigeria. Cent Afr J Med. 1997;43(8):231-4. 
10. 
van Hensbroek MB, Palmer A, Jaffar S, Schneider G, Kwiatkowski D. Residual neurologic sequelae after 
childhood cerebral malaria. J Pediatr. 1997;131(1 Pt 1):125-9. 
11. 
Brewster DR, Kwiatkowski D, White NJ. Neurological sequelae of cerebral malaria in children. Lancet. 
1990;336(8722):1039-43. 
12. 
Bangirana P, Idro R, John CC, Boivin MJ. Rehabilitation for cognitive impairments after cerebral malaria 
in African children: strategies and limitations. Trop Med Int Health. 2006;11(9):1341-9. 
13. 
Boivin MJ, Bangirana P, Byarugaba J, Opoka RO, Idro R, Jurek AM, et al. Cognitive impairment after 
cerebral malaria in children: a prospective study. Pediatrics. 2007;119(2):e360-6. 
14. 
WHO. WHO. Guidelines for the treatment of malaria, 2nd edition. 2010. Geneva: WHO; 2010. 
15. 
Bangirana P, Menk J, John CC, Boivin MJ, Hodges JS. The association between cognition and 
academic performance in Ugandan children surviving malaria with neurological involvement. PloS one. 
2013;8(2):e55653. 
16. 
Bangirana P, Musisi S, Boivin MJ, Ehnvall A, John CC, Bergemann TL, et al. Malaria with neurological 
involvement in Ugandan children: effect on cognitive ability, academic achievement and behaviour. Malaria 
journal. 2011;10:334. 
17. 
Carter JA, Ross AJ, Neville BG, Obiero E, Katana K, Mung'ala-Odera V, et al. Developmental 
impairments following severe falciparum malaria in children. Trop Med Int Health. 2005;10(1):3-10. 
18. 
Kariuki SM, Abubakar A, Newton CR, Kihara M. Impairment of executive function in Kenyan children 
exposed to severe falciparum malaria with neurological involvement. Malaria journal. 2014;13:365. 
19. 
Chomba E, Haworth A, Atadzhanov M, Mbewe E, Birbeck GL. The socioeconomic status of children with 
epilepsy in Zambia: implications for long-term health and well-being. Epilepsy Behav. 2008;13(4):620-3. 
20. 
Severe and complicated malaria. World Health Organization, Division of Control of Tropical Diseases 
[see comments]. Trans R Soc Trop Med Hyg. 1990;84(Suppl 2):1-65. 
21. 
Corbett D, Thornhill J. Temperature modulation (hypothermic and hyperthermic conditions) and its 
influence on histological and behavioral outcomes following cerebral ischemia. Brain Pathol. 2000;10(1):145-52. 
22. 
Greer DM, Funk SE, Reaven NL, Ouzounelli M, Uman GC. Impact of fever on outcome in patients with 
stroke and neurologic injury: a comprehensive meta-analysis. Stroke. 2008;39(11):3029-35. 
23. 
Laptook AR, Corbett RJ. The effects of temperature on hypoxic-ischemic brain injury. Clin Perinatol. 
2002;29(4):623-49, vi. 
24. 
Suz P, Vavilala MS, Souter M, Muangman S, Lam AM. Clinical features of fever associated with poor 
outcome in severe pediatric traumatic brain injury. Journal of neurosurgical anesthesiology. 2006;18(1):5-10. 
25. 
Arrich J, Holzer M, Herkner H, Mullner M. Cochrane corner: hypothermia for neuroprotection in adults 
after cardiopulmonary resuscitation. Anesthesia and analgesia. 2010;110(4):1239. 
26. 
Lin ZL, Yu HM, Lin J, Chen SQ, Liang ZQ, Zhang ZY. Mild hypothermia via selective head cooling as 
neuroprotective therapy in term neonates with perinatal asphyxia: an experience from a single neonatal 


 
Aggressive Antipyretics for Fever 
 
 
Control in CNS Malaria 
 
 
Version 5.3 
21 Jan 2021 
Page 31 of 33 
intensive care unit. Journal of perinatology : official journal of the California Perinatal Association. 
2006;26(3):180-4. 
27. 
Low E, Boylan GB, Mathieson SR, Murray DM, Korotchikova I, Stevenson NJ, et al. Cooling and seizure 
burden in term neonates: an observational study. Arch Dis Child Fetal Neonatal Ed. 2012;97(4):F267-72. 
28. 
Schulzke SM, Rao S, Patole SK. A systematic review of cooling for neuroprotection in neonates with 
hypoxic ischemic encephalopathy - are we there yet? BMC pediatrics. 2007;7:30. 
29. 
Smit E, Liu X, Jary S, Cowan F, Thoresen M. Cooling neonates who do not fulfil the standard cooling 
criteria - short and long term outcomes. Acta paediatrica. 2014. 
30. 
Choi HA, Badjatia N, Mayer SA. Hypothermia for acute brain injury--mechanisms and practical aspects. 
Nature reviews Neurology. 2012;8(4):214-22. 
31. 
Corry JJ. Use of hypothermia in the intensive care unit. World journal of critical care medicine. 
2012;1(4):106-22. 
32. 
Magnusson M, Dahl M, Cederberg J, Karlsson M, Sandstrom R. Pharmacodynamics of Carbamazepine-
mediated Induction of CYP3A4, CYP1A2, and Pgp as Assessed by Probe Substrates Midazolam,Caffeine, and 
Digoxin. Clinical Pharmacology & Therapeutics 2008;84(1):52-62. 
33. 
Scaravilli V, Tinchero G, Citerio G, Participants in the International Multi-Disciplinary Consensus 
Conference on the Critical Care Management of Subarachnoid H. Fever management in SAH. Neurocrit Care. 
2011;15(2):287-94. 
34. 
Crawley J, Smith S, Kirkham F, Muthinji P, Waruiru C, Marsh K. Seizures and status epilepticus in 
childhood cerebral malaria. Qjm. 1996;89(8):591-7. 
35. 
Idro R, Jenkins NE, Newton CR. Pathogenesis, clinical features, and neurological outcome of cerebral 
malaria. Lancet Neurol. 2005;4(12):827-40. 
36. 
WHO. Guidelines for the treatment of malaria. Geneva: WHO; 2015. Available from: 
http://www.who.int/malaria/publications/atoz/9789241549127/en/. 
37. 
WHO/WFN. Atlas: Country resources for neurological disorders. Geneva: WHO; 2004. 59 p. 
38. 
Long HY, Lell B, Dietz K, Kremsner PG. Plasmodium falciparum: in vitro growth inhibition by febrile 
temperatures. Parasitology research. 2001;87(7):553-5. 
39. 
Brandts CH, Ndjave M, Graninger W, Kremsner PG. Effect of paracetamol on parasite clearance time in 
Plasmodium falciparum malaria. Lancet. 1997;350(9079):704-9. 
40. 
John CC, Park GS, Sam-Agudu N, Opoka RO, Boivin MJ. Elevated serum levels of IL-1ra in children 
with Plasmodium falciparum malaria are associated with increased severity of disease. Cytokine. 
2008;41(3):204-8. 
41. 
John CC, Bangirana P, Byarugaba J, Opoka RO, Idro R, Jurek AM, et al. Cerebral malaria in children is 
associated with long-term cognitive impairment. Pediatrics. 2008;122(1):e92-9. 
42. 
Dobbie M, Crawley J, Waruiru C, Marsh K, Surtees R. Cerebrospinal fluid studies in children with 
cerebral malaria: an excitotoxic mechanism? Am J Trop Med Hyg. 2000;62(2):284-90. 
43. 
Medana IM, Day NP, Salahifar-Sabet H, Stocker R, Smythe G, Bwanaisa L, et al. Metabolites of the 
kynurenine pathway of tryptophan metabolism in the cerebrospinal fluid of Malawian children with malaria. J 
Infect Dis. 2003;188(6):844-9. 
44. 
Becker K, Rahlfs S, Nickel C, Schirmer RH. Glutathione--functions and metabolism in the malarial 
parasite Plasmodium falciparum. Biological chemistry. 2003;384(4):551-66. 
45. 
Greve B, Lehman LG, Lell B, Luckner D, Schmidt-Ott R, Kremsner PG. High oxygen radical production is 
associated with fast parasite clearance in children with Plasmodium falciparum malaria. J Infect Dis. 
1999;179(6):1584-6. 
46. 
Clark IA, Mackie EJ, Cowden WB. Injection of free radical generators causes premature onset of tissue 
damage in malaria-infected mice. The Journal of pathology. 1986;148(4):301-5. 
47. 
Potchen MJ, Kampondeni SD, Seydel KB, Birbeck GL, Hammond CA, Bradley WG, et al. Acute Brain 
MRI Findings in 120 Malawian Children with Cerebral Malaria: New Insights into an Ancient Disease. AJNR Am 
J Neuroradiol. 2012;10.3174/ajnr.A3035. 
48. 
Udomsangpetch R, Pipitaporn B, Silamut K, Pinches R, Kyes S, Looareesuwan S, et al. Febrile 
temperatures induce cytoadherence of ring-stage Plasmodium falciparum-infected erythrocytes. Proceedings of 
the National Academy of Sciences of the United States of America. 2002;99(18):11825-9. 
49. 
Marinkovic M, Diez-Silva M, Pantic I, Fredberg JJ, Suresh S, Butler JP. Febrile temperature leads to 
significant stiffening of Plasmodium falciparum parasitized erythrocytes. American journal of physiology Cell 
physiology. 2009;296(1):C59-64. 
50. 
Fox LL, Taylor TE, Pensulo P, Liomba A, Mpakiza A, Varela A, et al. Histidine-rich protein 2 plasma 
levels predict progression to cerebral malaria in Malawian children with Plasmodium falciparum infection. J 
Infect Dis. 2013;208(3):500-3. 


 
Aggressive Antipyretics for Fever 
 
 
Control in CNS Malaria 
 
 
Version 5.3 
21 Jan 2021 
Page 32 of 33 
51. 
Seydel KB, Fox LL, Glover SJ, Reeves MJ, Pensulo P, Muiruri A, et al. Plasma concentrations of 
parasite histidine-rich protein 2 distinguish between retinopathy-positive and retinopathy-negative cerebral 
malaria in Malawian children. J Infect Dis. 2012;206(3):309-18. 
52. 
Lell B, Sovric M, Schmid D, Luckner D, Herbich K, Long HY, et al. Effect of antipyretic drugs in children 
with malaria. Clin Infect Dis. 2001;32(5):838-41. 
53. 
Krishna S, Pukrittayakamee S, Supanaranond W, ter Kuile F, Ruprah M, Sura T, et al. Fever in 
uncomplicated Plasmodium falciparum malaria: randomized double- 'blind' comparison of ibuprofen and 
paracetamol treatment. Trans R Soc Trop Med Hyg. 1995;89(5):507-9. 
54. 
Kofoed PE, Ursing J, Rodrigues A, Rombo L. Paracetamol versus placebo in treatment of non-severe 
malaria in children in Guinea-Bissau: a randomized controlled trial. Malaria journal. 2011;10:148. 
55. 
Agbolosu NB, Cuevas LE, Milligan P, Broadhead RL, Brewster D, Graham SM. Efficacy of tepid 
sponging versus paracetamol in reducing temperature in febrile children. Ann Trop Paediatr. 1997;17(3):283-8. 
56. 
den Hertog HM, van der Worp HB, van Gemert HM, Dippel DW. Acetaminophen for temperature 
reduction in acute stroke: potential but unproven benefits. Stroke. 2007;38(11):e131; author reply e2. 
57. 
Graham GG, Davies MJ, Day RO, Mohamudally A, Scott KF. The modern pharmacology of paracetamol: 
therapeutic actions, mechanism of action, metabolism, toxicity and recent pharmacological findings. 
Inflammopharmacology. 2013;21(3):201-32. 
58. 
Karbasi SA, Modares-Mosadegh M, Golestan M. Comparison of antipyretic effectiveness of equal doses 
of rectal and oral acetaminophen in children. Jornal de pediatria. 2010;86(3):228-32. 
59. 
Bushra R, Aslam N. An Overview of Clinical Pharmacology of Ibuprofen. Oman Medical Journal. 
2010;25(3):155-1661. 
60. 
Management of childhood fever. Lancet. 1991;338(8774):1049-50. 
61. 
Casteels-Van Daele M. Management of childhood fever. Lancet. 1991;338(8779):1408. 
62. 
Gupta H, Shah D, Gupta P, Sharma KK. Role of paracetamol in treatment of childhood Fever: a double-
blind randomized placebo controlled trial. Indian Pediatr. 2007;44(12):903-11. 
63. 
Vinh H, Parry CM, Hanh VT, Chinh MT, House D, Tham CT, et al. Double blind comparison of ibuprofen 
and paracetamol for adjunctive treatment of uncomplicated typhoid fever. Pediatr Infect Dis J. 2004;23(3):226-
30. 
64. 
Erlewyn-Lajeunesse MD, Coppens K, Hunt LP, Chinnick PJ, Davies P, Higginson IM, et al. Randomised 
controlled trial of combined paracetamol and ibuprofen for fever. Arch Dis Child. 2006;91(5):414-6. 
65. 
Pierce CA, Voss B. Efficacy and safety of ibuprofen and acetaminophen in children and adults: a meta-
analysis and qualitative review. The Annals of pharmacotherapy. 2010;44(3):489-506. 
66. 
Section on Clinical P, Therapeutics, Committee on D, Sullivan JE, Farrar HC. Fever and antipyretic use 
in children. Pediatrics. 2011;127(3):580-7. 
67. 
Southey ER, Soares-Weiser K, Kleijnen J. Systematic review and meta-analysis of the clinical safety and 
tolerability of ibuprofen compared with paracetamol in paediatric pain and fever. Current medical research and 
opinion. 2009;25(9):2207-22. 
68. 
Nwanyanwu OC, Ziba C, Kazembe PN. Paracetamol and ibuprofen for treatment of fever in Malawian 
children aged less than five years. Trans R Soc Trop Med Hyg. 1999;93(1):84. 
69. 
Birbeck GL, Beare N, Lewallen S, Glover SJ, Molyneux ME, Kaplan PW, et al. Identification of malaria 
retinopathy improves the specificity of the clinical diagnosis of cerebral malaria: findings from a prospective 
cohort study. Am J Trop Med Hyg. 2010;82(2):231-4. 
70. 
Postels DG, Taylor TE, Molyneux M, Mannor K, Kaplan PW, Seydel KB, et al. Neurologic outcomes in 
retinopathy-negative cerebral malaria survivors. Neurology. 2012;79(12):1268-72. 
71. 
Postels DG, Li C, Birbeck GL, Taylor TE, Seydel KB, Kampondeni SD, et al. Brain MRI of children with 
retinopathy-negative cerebral malaria. Am J Trop Med Hyg. 2014;91(5):943-9. 
72. 
Nielsen N, Wetterslev J, Cronberg T, Erlinge D, Gasche Y, Hassager C, et al. Targeted temperature 
management at 33 degrees C versus 36 degrees C after cardiac arrest. N Engl J Med. 2013;369(23):2197-206. 
73. 
Newton CR, Chokwe T, Schellenberg JA, Winstanley PA, Forster D, Peshu N, et al. Coma scales for 
children with severe falciparum malaria. Trans R Soc Trop Med Hyg. 1997;91(2):161-5. 
74. 
Efird J. Blocked randomization with randomly selected block sizes. International journal of environmental 
research and public health. 2011;8(1):15-20. 
75. 
WHO. Guidelines for the Treatment of Malaria. Second ed. Genev: WHO Press; 2010. 194 p. 
76. 
Whitehead J. Sample size calculations for ordered categorical data Statist Med. 1993;12:2257-71. 
77. 
Guideline one: minimum technical requirements for performing clinical electroencephalography. 
American Electroencephalographic Society. J Clin Neurophysiol. 1994;11(1):2-5. 
78. 
Paul P, Pennell ML, Lemeshow S. Standardizing the power of the Hosmer-Lemeshow goodness of fit 
test in large data sets. Stat Med. 2013;32(1):67-80. 


 
Aggressive Antipyretics for Fever 
 
 
Control in CNS Malaria 
 
 
Version 5.3 
21 Jan 2021 
Page 33 of 33 
 

ICF_004.pdf: 
Consent Form: Randomized Trial of Aggressive Antipyretics for CNS Malaria (PI: Birbeck, GL)
Version 4.7 (for Zambia sites)
Page 1 of 9
16 Apr 2020
Informed Consent Form (ICF) for the parents/guardians of children between the ages of 2 
and 11 years presenting to either (1) UTH Children’s Hospital in Lusaka or (2) Chipata 
Central Hospital in Chipata, Eastern Province with the combination of malaria and new-onset 
central nervous system (CNS) impairment, and who are interested in participating in the 
Malaria Fever Control Study.
Principal Investigator:
Gretchen L. Birbeck, MD MPH DTMH
Organization:
UTH Neurology Research Office (UTH-NRO)
Sponsor:
National Institute of Neurologic Disorders and Stroke (NINDS), 
USA
Proposal:
Aggressive Antipyretics in CNS Malaria: a Randomized-
Controlled Trial Assessing Antipyretic Efficacy and Parasite 
Clearance
Consent Form Version:
V4.7 (16 Apr 2020)
This Informed Consent Form (ICF) has two parts:

Information Sheet (to share information about the study with you)

Certificate of Consent (for signatures if you agree that your child may participate)
You will be given a copy of the full Informed Consent Form
PART I: Information Sheet
Introduction
Your child has malaria and needs admission to the hospital for care. We are seeking your 
permission for your child to participate in a clinical trial of antipyretics (Calpol and Nurofen) 
for fever reduction. Calpol is the name used by the company that makes the medicine we are 
using, but you may know this medicine by the name paracetamol or Panadol. Similarly, 
Nurofen is the name used by the company that makes the medicine we are using, but you may 
know this medicine by the name ibuprofen or Brufen.
Purpose
Paracetamol and ibuprofen are medications commonly used for treating fevers in children, 
but usually children with malaria only receive paracetamol and they are only given a 
medication for fever reduction if their fever reaches 38.5ºC or higher. In previous research we 
found that children with higher fevers during their acute malarial illness had a greater risk of 
developing neurologic problems after they recovered from the infection and we know that in 
other conditions affecting the nervous system, therapies that prevent the patient from 
becoming febrile result in better neurologic outcomes.
UTH  NRO
University Teaching Hospital 
Neurology Research Office
RSRB Approval Date: 12/8/2020
Expiration Date: 12/7/2021


Consent Form: Randomized Trial of Aggressive Antipyretics for CNS Malaria (PI: Birbeck, GL)
Version 4.7 (for Zambia sites)
Page 2 of 9
16 Apr 2020
Type of Research Intervention
This is a randomized, double-blinded, placebo-controlled study comparing ‘usual care’ for 
fever in children with CNS malaria to a more aggressive approach that may minimize both 
fevers and the complications associated with fever.
Participant selection
Your child has malaria and needs admission to the hospital for care.
Questions to assess understanding: Do you know why your child has been identified 
as a potential research participant? Do you know what the study is about? 
Voluntary Participation
Your child’s participation in this research study is entirely voluntary. If you do not wish for 
your child to participate in this clinical trial, your child will continue to be cared for here. No 
care will be withheld.
Questions to assess understanding: If you decide that you do not want your child to 
take part in this research study, do you know what your options for him/her are? Do 
you know that you do not have to accept that your child takes part in this research 
study? Do you have any questions?
Information on the Trial Drugs: Calpol (paracetamol) and Nurofen (ibuprofen)
1) This study is a phase III (3) clinical trial. “Phase III” means that we are assessing the study 
drugs for their efficacy (ideal conditions), effectiveness (real world conditions) and safety, 
and are doing so in what are recommended doses for each drug. 
2) The two drugs to be used, Calpol and Nurofen, will be used in approved doses for an 
approved purpose (fever). Because this is a double-blind study, the clinical staff and you 
should and will not know which study participant is in each group (usual care vs. aggressive 
antipyretics). Thus, the drugs required re-packaging, so the drugs are those registered with 
and approved by the Zambian Medicines Regulatory Authority (ZaMRA), and purchased 
from manufacturers in Africa. The re-packaged drug labels include the individual 
participant’s study ID numbers but do not tell what is inside the bottle (i.e., the real drug or 
instead a placebo), only the study statistician knows this blinding information. 
3) Both study drugs have been used for many decades throughout the world and have been 
shown to be very safe when used in recommended doses for approved reasons.  
4) Known side-effects/toxicity of the two study drugs: this is described below in the “Side 
Effects, Risks and Discomforts” section. All other medicines that will and may be used to 
treat your child, such as to treat your child’s malaria infection and for seizures, are those 
approved for use by the Zambia Medicines Regulatory Authority (ZaMRA).
Procedures and Protocol
A. Unfamiliar Procedures
In this study, we are going to randomly assign children to one of two groups, either the ‘usual 
care’ group, or the ‘aggressive antipyretic therapy’ group. In the ‘usual care’ group, children 
will get treatment with Calpol if they get a temperature of 38.5ºC or higher, and will also be 
cooled with a fan if the temperature remains high on Calpol alone. In the ‘aggressive 
antipyretic therapy’ group, children will get Calpol and Nurofen immediately and then every 
6 hours for 72 hours even if they do not have a temperature above 38.5ºC. If their fever 
RSRB Approval Date: 12/8/2020
Expiration Date: 12/7/2021


Consent Form: Randomized Trial of Aggressive Antipyretics for CNS Malaria (PI: Birbeck, GL)
Version 4.7 (for Zambia sites)
Page 3 of 9
16 Apr 2020
remains high they will also be cooled with a fan. We do not know if giving Calpol and 
Nurofen immediately and together will result in less fevers. This study is designed to 
determine if there is a reduction in fevers in the children who receive aggressive antipyretic 
therapy vs. routine care. All the children who have a fever will receive active medication to 
reduce that fever. Some will receive the active medication before a fever reaches 38.5, if their 
temperature goes over 38.5 they will be given inactive medication (placebo). This is the 
aggressive medication group. The second group, usual care, will receive inactive pills 
(placebo) initially, and active medication if their temperature goes above 38.5. We will not 
know which group your child is in. It is important to remember that all children who have a 
fever will receive treatment for their fever. If you agree to allow your child to participate in 
this research study, your child will be assigned by chance (like flipping a coin) to receive 
aggressive antipyretics vs. ‘routine care’. Neither you nor your child’s doctor will know 
which group he or she is assigned to. 
B. Description of the Process
The medications are both liquids to be given by mouth every 6 hours for the next 3 days. If 
your child is unable to swallow the medication, we will place a tube in your child’s nose 
going into the stomach and the medication will be delivered through that tube until your child 
wakes up. Once your child is awake and able to take the medication, we will remove this 
tube. All children in this study will have a small sticker placed in their axilla and attached to a 
machine to measure their temperature for 3 days. All children in this study will have blood 
taken every 6 hours by finger pricks to check the parasite count and glucose and kidney 
function. The total volume of blood taken over the full course of the study will be less than 2 
mls. If your child is confused or sleepy from the malaria and cannot be easily awakened, we 
will also place some metal discs on the head attached with glue to record your child’s brain 
activity. This is to measure continuous electroencephalogram (EEG) activity, or the electrical 
activity in the brain. The EEG will allow us to know if your child is having any seizures that 
we cannot see by just looking at the child. Seizures can happen in the brain and not be 
apparent by just looking. 
Duration 
Your child’s participation in the study would last for 72 hours (3 days). After that, if your 
child requires continued hospitalization, s/he will receive all standard care as available at 
UTH. If there is need to monitor and/or manage study-related adverse events, a 30-day 
follow-up visit may be scheduled according to each study site’s clinical care protocol and at 
the discretion of the study clinician discharging the patient.
Questions to assess understanding: Can you tell me if you remember how long your 
child would need to be in the study? How often would we be giving the study drugs to 
your child? How often would we need to complete finger pricks to check for malaria 
parasites and for the other study tests? After your child completed the in-hospital 
study period and was discharged, would we need to see your child again? Do you 
have any other questions? Do you want me to go through the procedures again?
Side Effects, Risks and Discomforts
What are the specific risks to your child if he/she participates in this research project? 
Research staff will be reviewing your child’s medical records and recording information 
important for the study in a research file. To limit the risk to your privacy, when we record 
data in the research file, a study ID and not your child’s name will be recorded. If your child 
is in this study and they are unable to swallow, then they will have a nasogastric tube (NGT) 
RSRB Approval Date: 12/8/2020
Expiration Date: 12/7/2021


Consent Form: Randomized Trial of Aggressive Antipyretics for CNS Malaria (PI: Birbeck, GL)
Version 4.7 (for Zambia sites)
Page 4 of 9
16 Apr 2020
placed so that the study medications can be given to them. If your child is not in the study, no 
NGT will be placed today. This tube may cause nasal or throat irritation or bleeding. This is 
usually a minor problem but in a small number of cases this could result in the medication 
going into the child’s lungs and would require removal of the tube and further treatment, like 
suction. As part of the research, when your child is pricked for malaria parasite counts, we 
will take an extra small tube of blood (hold up capillary tube). Malaria can cause problems 
with bleeding, poor liver function and poor kidney function. It is possible that the 
medications given in this clinical trial could worsen the problems caused by malaria. The 
Nurofen could cause your child to have problems with bleeding. We will monitor for this 
closely and if we see any signs of problems with bleeding, we will stop the study 
medications. The glue and metal discs for the EEG are not harmful although the glue has a 
strong smell and some people get mild skin irritation where the glue and electrodes are 
placed.  The Calpol and Nurofen are generally safe medications but stomach irritation and 
stomach pain can result from taking these medications. These medications might also worsen 
problems the malaria causes to your child’s liver and kidneys. We will monitor for signs that 
the medications are causing problems and stop treatment if needed. If your child experiences 
any adverse effects from the drug, we will provide care and treatment plus any other 
assistance as may be deemed necessary.
Questions to assess understanding: Do you understand that, while the research study 
is ongoing, no one would know to which group (either the ‘usual care’ group or the 
‘aggressive antipyretic therapy’ group) your child is assigned? Do you understand 
that your child may have some unwanted side effects from the medicines? Do you 
understand that these side effects can happen whether or not your child is in the 
research study? Do you have any questions?
Benefits 
What are the possible benefits to your child if he/she participates in this research project? The 
EEGs may alert us to seizures we cannot detect otherwise and will allow us to treat these 
seizures, which might otherwise go without treatment possibly resulting in brain injury. If 
your child is randomized to aggressive antipyretics, your child may be more comfortable 
during this admission since in addition to fever reduction, these medications also treat pain 
(e.g. the headache usually associated with malaria).
Reimbursements
There are no anticipated costs to be incurred by individual as a direct result from participating 
in this study. If you agree for your child to be in this study, we will provide you and your child 
with transportation home or funds for transportation home.
Questions to assess understanding: Can you tell me if you have understood correctly 
the benefits that your child will have if you allow him/her to take part in the study? 
Do you know if the study will pay for your and your child's travel costs and your time 
lost, and do you know how much you will be reimbursed? Do you have any other 
questions?
Confidentiality
The information about your child from this study will be kept here at University Teaching 
Hospital (UTH) or Chipata Central Hospital, depending on where your child is admitted and 
enrolled in the study, in locked study offices. This information will be used by researchers on 
this study. In addition, this information will be made available to the Independent Study 
RSRB Approval Date: 12/8/2020
Expiration Date: 12/7/2021


Consent Form: Randomized Trial of Aggressive Antipyretics for CNS Malaria (PI: Birbeck, GL)
Version 4.7 (for Zambia sites)
Page 5 of 9
16 Apr 2020
Monitors, the Research Ethics Committees at this hospital and the University of Rochester, 
Michigan State University, the Zambia Medicines Regulatory Authority and the US National 
Institute of Health. Your privacy will be protected to the maximum extent allowable by law. By 
signing this consent form you are agreeing that these entities can have access to your child’s 
records. For all other purposes, your child will be assigned a study identifier and information 
sent outside of UTH or Chipata Central Hospital will include this identifier, not your child’s 
name. The study records will be kept for a minimum of three years following the completion of 
the study.
Questions to assess understanding: Did you understand the procedures that we will 
be using to make sure that any information that we as researchers collect about you 
and/or your child will remain confidential? Do you have any questions about them?  
Sharing of the results
While your child is participating in this study, we will provide you immediately with any new 
findings about this study or the antipyretic medications. A description of this clinical trial will 
be available on www.ClinicalTrials.gov, as required by U.S. law.  This website will not 
include information that can identify you. At most, the website will include a summary of the 
results. You can search this Web site at any time.
Right to Refuse or Withdraw
If you agree to your child’s participation now, but later decide you do not wish for your child to 
be part of our study, you may withdraw the child from participation at any time. On the side of 
investigators, there are no foreseen circumstances under which the principal investigator may 
terminate a subject’s participation in the study.
Alternatives to participating
If you do not wish for your child to participate in this clinical trial, your child will continue to 
be cared for here. No care will be withheld. Your child’s fevers will be treated with the ‘usual 
care’ detailed above. This will include treatment with Calpol, additional treatment with 
Nurofen if Calpol does not lower the fever, and the usual amount of EEGs, temperature 
monitoring, an additional small tube of blood when your child is getting a finger prick for 
parasites, and an NG tube if your child cannot swallow the medicines.
Who to Contact
If you have any questions about your child’s participation as a subject in human research or 
need to contact someone about a research-related injury, you may contact the investigators in 
charge. Or, you may contact the Chair for the Research Ethics Committee:
Dr. Gretchen Birbeck 0978-086957
Lusaka:
Dr. Manoj Mathews 0977-625727
Dr. Musaku Mwenechanya 0966-766052
UTH Neurology Research Office
Private Bag RW-1X
Ridgeway UTH
Lusaka, Zambia
Chipata:
UNZA Biomedical Research Ethics 
Committee
Ridgeway Campus
PO Box 50110
Lusaka, Zambia
Tele 01-256067
Email: unzarec@unza.zm 
RSRB Approval Date: 12/8/2020
Expiration Date: 12/7/2021


Consent Form: Randomized Trial of Aggressive Antipyretics for CNS Malaria (PI: Birbeck, GL)
Version 4.7 (for Zambia sites)
Page 6 of 9
16 Apr 2020
Dr. Suzanna Mwanza 096-1517604
Department for Paediatrics & Child Health
Chipata Central Hospital
Chipata, Eastern Province, Zambia
RSRB Approval Date: 12/8/2020
Expiration Date: 12/7/2021


Consent Form: Randomized Trial of Aggressive Antipyretics for CNS Malaria (PI: Birbeck, GL)
Version 4.7 (for Zambia sites)
Page 7 of 9
16 Apr 2020
PART II: Certificate of Consent
Parent/Guardian Certificate of Consent 
I have been invited to have my child participate in research of treatment of fever for malaria 
in children also suffering from related brain dysfunction. I have read the foregoing 
information, or it has been read to me. I have had the opportunity to ask questions about it 
and any questions that I have asked have been answered to my satisfaction. I consent 
voluntarily for my child to participate as a participant in this study.
Print Name of Participant
_________________________
Print Name of Parent or Guardian
_________________________
Signature of Parent or Guardian 
_________________________
Date 
_________________________
Day/month/year
 
If Parent/Guardian is Illiterate
A literate witness must sign (if possible, this person should be selected by the participant and 
should have no connection to the research team). Participants who are illiterate should 
include their thumb print as well.  
I have witnessed the accurate reading of the consent form to the parent/guardian of the 
potential participant, and the individual has had the opportunity to ask questions. I confirm 
that the individual has given consent freely. 
Print Name of Witness_________________________
AND
Thumbprint of parent
Signature of Witness _________________________
Date 
_________________________
Day/month/year
Statement by the Researcher/Person Taking Consent
I have accurately read out the information sheet to the parent/guardian of the potential 
participant, and to the best of my ability made sure that the person understands that the 
following will be done:
1. Randomization
2. In-hospital for 3 days study
3. Everyone gets standard/usual treatment, but some children will also receive additional 
treatment for their fevers
I confirm that the parent/guardian was given an opportunity to ask questions about the 
study, and all the questions asked by the parent/guardian have been answered correctly and to 
the best of my ability. I confirm that the individual has not been coerced into giving consent, 
and the consent has been given freely and voluntarily. 
RSRB Approval Date: 12/8/2020
Expiration Date: 12/7/2021


Consent Form: Randomized Trial of Aggressive Antipyretics for CNS Malaria (PI: Birbeck, GL)
Version 4.7 (for Zambia sites)
Page 8 of 9
16 Apr 2020
  
A copy of this ICF has been provided to the participant.
Print Name of Researcher/Person Taking the Consent
_________________________
Signature of Researcher/Person Taking the Consent
_________________________
Date
_________________________
Day/month/year
Screening number:
sZ  __  __  __
Study Identification (ID) number:
Z  __  __  __
RSRB Approval Date: 12/8/2020
Expiration Date: 12/7/2021


Consent Form: Randomized Trial of Aggressive Antipyretics for CNS Malaria (PI: Birbeck, GL)
Version 4.7 (for Zambia sites)
Page 9 of 9
16 Apr 2020
RSRB Approval Date: 12/8/2020
Expiration Date: 12/7/2021